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ABSTRACT
Polybrominated diphenyl ethers (PBDEs) are flame retardant chemicals of toxicological 
concern present in humans, wildlife, and the environment. Deca-BDE is the highest 
production product due to historical use patterns and recent regulatory limitations on the 
other two commercial formulations (Penta-BDE and Octa-BDE) in the U.S and Europe. 
The EU banned Deca-BDE starting July 1, 2008. However, it remains in usage in North 
America and elsewhere in the world. BDE-209 is the dominant congener in all Deca- 
BDE commercial products. BDE-209 has been reported to under go metabolic 
debromination to lesser brominated and more toxic and bioaccumulative congeners. 
However, insufficient data are available on this process. It has also been observed that 
congener profiles and BDE-209 levels in terrestrial organisms differ from most aquatic 
species, indicating accumulation or metabolic dissimilarity. The goal of this in ovo study 
is to determine the biotransformation and tissue distribution of BDE-209 after injection 
into the yolk-sac of embryonic chickens. An emulsion formulation was employed to 
better distribute the hydrophobic BDE-209 within the eggs in an attempt to better mimic 
“natural” exposure of embryos. Acute mortality from BDE-209 yolk injection was 
observed. An LD50 value of 44 pg/egg (740 ng/g ww) was determined for embryonic 
chickens in this study. Concentrations of BDE-209 and possible metabolic degradates 
were determined in five compartments of the embryos (yolk, brain, liver, heart and 
remaining carcass). The results indicated that some BDE-209 was mobilized from the 
yolk, into the carcass, liver, brain, and heart tissues of the developing chicken embryo 
prior to pipping. However, 80% of the dose was detected as BDE-209 in the yolk sac. 
Additional BDE-209 would likely have been assimilated following hatching and 
resorption of the remaining yolk. Nona-BDEs were detected in all of the liver and yolk 
samples from BDE-209 exposed eggs. The congener profiles of the different tissues did 
not indicate that significant metabolic debromination of BDE-209 occurred within the 
developing embryos.
Toxicology of Decabromodiphenyl Ether in Avian Embryos: 
Disposition of the Flame Retardant BDE-209 in Yolk-injected 
Chicken Embryos {Gallus gallus)
INTRODUCTION
Polybrominated diphenyl ethers (PBDEs) are flame retardant chemicals present in 
many industrial and household products. PBDEs have been widely used in 
thermoplastics, polyurethane foam and in textile coatings (Watanabe and Sakai 2003, 
Hale et al. 2003, Law et al. 2006). The chemical structures of PBDEs are reminiscent of 
polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs) (Figure LI). 
There are a total of 209 individual PBDE congeners possible, as is the case for PCBs and 
PBBs, but a limited number are abundant in the commercial mixtures (LaGuardia et al.
2006). The ether linkage between the two phenyl rings in PBDEs, and the presence of 
bromines versus chlorines, results in these molecules bearing a closer resemblance to 
natural hormone molecules such as iodine-containing thyroxine than the PCBs (Figure 
1.2).
Figure LI: PCB versus PBDE
The top molecule is a polychlorinated biphenyl (PCB) congener; specifically 2 .2 ’,4 .4’-tetrachlorobiphenyl 
(PCB-47) . The bottom image is the molecular structure o f  the polybrominated biphenyl ether (PBDE) 
congener (B D E -100). (v\ w vv.sI h.vv isc.ed u/ eh d/orga n ics/c 1 c in m k>m.p 1 n ))
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Figure 1.2: Thyroxine, T4
HO c — c
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Three PBDE commercial mixtures have been in wide commercial use since the 
1970s. These products vary in regards to the degree of bromination of their constituent 
congeners. Penta-BDE is the least brominated mixture. Its dominant constituents exhibit 
from three to six bromines. Octa-BDE contains components that average eight bromine 
substitutions, but major congeners exhibit six to nine substitutions. Deca-BDE consists 
of about 97% of the fully brominated BDE-209 congener (Figure 1.3).
Figure 1.3: Decabromodiphenyl ether, BDE-209
B r r r - t /
Br,
Br B r
rn e t . i i  :•
The commercial PBDE mixtures are used in different polymer products. The bulk 
of Penta-BDE has been employed as an additive in polyurethane foams, common in
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furniture. It appears that Penta-BDE was also used to a limited extent in some circuit 
boards until the mid 1990s. Octa-BDE was a more modest use product, mostly as a flame 
retardant additive in acrylonitrile-butadiene-styrene (ABS). ABS is a high-impact plastic 
used in office electronics, automobiles and kitchen appliances. (Hale et al. 2003, 
Watanabe and Sakai 2003)
In 2001, Deca-BDE constituted 83% of total global PBDE use (Hale et. al 2003), 
primarily as an additive to high-impact polystyrene1. This plastic is commonly used in 
the housings of various electronic devices such as televisions, computers, and related 
products. Deca-BDE is also used in latex back-coatings for textiles. Polymer products 
can contain up to 30% Deca -BDE by weight. With the cessation of the U.S. production 
of Penta-BDE and Octa-BDE in December 2004, Deca-BDE remained as the sole 
commercial PBDE product on the North American market.
Deca-BDE is listed as a toxic, high production volume chemical by the US EPA. 
As such, it is subject to annual release reporting by US industries using this chemical.
The Toxic Release Inventory Program (TRI) maintains a database on chemical release 
documentation going back to 1988. The TRI was originally created under Section 313 of 
the Emergency Planning and Community Right to Know Act (EPCRA). The Pollution 
Prevention Act of 1990 expanded TRI to pursue data on source reduction as well as 
release information. These data are available on-line at the EPA website. Following 
the methods from Hale et al. (2006) a brief analysis of these data was run to update the 
dataset of Deca-BDE releases to the environment over the last two decades. The data 
from the TRI are accumulated on a voluntary basis, therefore some considerations of the
1 http://www.bsef.com/uploads/library/BSEF_factsheet_Deca-BDE_l 60108.pdf
2 http://www.epa.gov/TRI/
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data quality can not be assured. For more information on this matter the EPA has 
released a guidance Document entitled “The Toxics Release Inventory (TRI) and Factors 
to Consider When Using TRI Data.”
Figure 1.4: Deca-BDE waste and release figures from the EPA Toxic Release
Inventory
1400
0  T otal Waste 
□  Total Release
1991 1993 1995 1997 1999 2001 2003 2005 2007
Year
The global demand for Deca-BDE in 1999 was 54,800 metric tons. (Watanabe 
and Sakai, 2003) The American market represented 44% of total global demand, the 
Asian 42%, and the European consumption only 14%. Total DecaBDE in US waste for 
1999 was 1185 metric tons or 2% of the global demand. Law et al. 2006 reported the 
estimated annual production of Deca-BDE to be 30,000 metric tones worldwide.
Hale et al (2009) examined temporal trends of PBDE concentrations in Chicago 
biosolids (stabilized sewage sludge) from the 1970s to 2008. The sludge samples showed 
a parabolic trend for the Penta-BDE product over time, with peak concentrations around
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the year 2002 and then a decrease (Hale et al. 2009.) This finding is consistent with the 
end of Penta-BDE production in 2004. The Deca-BDE concentrations in the Chicago 
sewage sludge increased over time. Continued release overtime and high persistence 
would support such a trend. Gerecke et al. (2006) found BDE209 to have a half-life of 
700 days in anaerobic sewage sludge.
1.1: PBDE Timeline
1970s Manufacturing of PBDEs begins. (Hale et al. 2006)
1981 PBDEs first detected in a river downstream from a textile plant in Stockholm.
2004 The European Union (EU) bans the Penta-BDE and Octa-BDE formulations. 
(Kierkegaard et al. 2009)
2004 U.S. PBDE manufacturers, Abermarle Chemical and Great Lakes Chemical, 
enter into an agreement with the U.S. EPA to cease production of the Penta-BDE 
and Octa-BDE products.
2005 The EU grants a four-year postponement of the ban on Deca-BDE.
2007 Maine and Washington States ban the use of Deca-BDE in electronics and new 
mattresses and other furnishings (Kierkegaard, 2009)
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2008 The EU regulates all uses of Deca-BDE through the Registration Evaluation
Authorization of Chemicals (REACH) Program.3
There are regulatory differences between the U.S. and Europe with regard to 
PBDEs. Most usage of Penta-BDE and Octa-BDE ceased in the EU due to 
environmental concerns, well before the formal 2004 ban . In the United States their 
usage continued until their sole manufacturer, Great Lakes Chemical Company, 
voluntarily entered into an agreement with the U.S. EPA to end production by December 
2004. Deca-BDE is now believed to be the only PBDE product remaining on the market 
in the US and abroad. But its safety remains a controversial issue. Deca-BDE is an 
effective flame retardant and a high production volume chemical, generating significant 
profits for its manufacturers.
PBDEs have been identified and quantified in many types of environmental and 
human samples and concentrations have risen therein since the 1970s (Hites 2004). 
Burdens in US samples tend to be higher than in European ones, most likely due to 
earlier regulatory actions taken in Europe..
Deca-BDE is a persistent organic pollutant. The major BFR manufacturers have 
historically claimed that Deca-BDE does not bioaccumulate and has extremely low 
bioavailability. Levels in aquatic organisms are typically much lower than the less 
brominated congeners. However, recent research has reported that BDE -209 was 
disproportionately high versus other PBDE congeners in some terrestrial organisms, e.g. 
grizzly bears (Christensen et al. 2005), red foxes (Voorspoels, 2007) and selected bird 
species (Lindberg et al. 2004, Chen et al. 2007, Potter et al. 2009). The levels of BDE-
’ http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:131:0007:0012:EN:PDF
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209 in terrestrial organisms may be linked with the proximity of the food web to point 
sources of PBDE pollution. For example, (Potter et al. (2009) reported that BDE-209 
levels in peregrine falcons (Falco peregrinus) from the Chesapeake Bay region were 
significantly correlated with population densities.
1.2: Presence of BDE-209 in Birds and the Environment
The fate and persistence of organic compounds is directly related to their structure 
and physical-chemical properties. BDE-209 has an octanol/water partitioning coefficient 
(log Kmv) of 8.70. (Waina and Dugani, 2003) This high value equates with the 
compound being very hydrophobic. The molecular size of BDE-209 and modest 
lipophilicity led many to believe it would not bioaccumulate. Elowever, the literature 
shows that BDE-209 is detectable in humans, mammals, birds, soils, plants, sewage 
sludge, and indoor dust (Voorspoels et al. 2007, Christensen et al. 2005, Hale at al. 2003, 
Law et al. 2008).
In 2008, Law et al. reviewed published data on brominated flame retardants 
(BFRs) in the European and Asian environments, particularly the concentrations and 
trends of BDE209 in biotic and abiotic media. The increasing trend in Europe appeared to 
be a leveling off. While, BDE209 concentrations continued to increase in Asian 
environments. The leading theory behind this is that the prevalence of electronics 
recycling in Asia results in large releases of BDE209 into the environment. Law et al. 
(2008) also highlighted the difficulties in analyzing samples for BDE209, in part due to 
its low volatility and thermal instability.
Christensen et al. (2005) analyzed fat tissue of grizzly bears from British 
Columbia and reported significant differences in the congener profiles of bears feeding in 
a maritime versus a terrestrial environment. The differences in diet were determined 
using stable isotope analysis. Enriched 513C values indicated more marine food items in 
the diet, while enriched 515N values indicated higher trophic prey items. Total PBDEs 
detected were not statistically different between the two groups. However, the congener 
profiles between the two were remarkably different. The maritime bears contained a 
preponderance of lower brominated congeners, i.e. BDE-47>209>99>100>153. The 
profiles of inland bears were dominated by more heavily brominated congeners 
209>47>207>208.
Another study examining moss samples (Mariussen et al., 2005) further 
demonstrated that BDE-209 is capable of entering the terrestrial food web.
Concentrations of BDE-209 in moss samples from Norway ranged from 0.11 to 1.59 
pg/kg dw. BDE209 was the dominant congener therein, 85% of the total PBDEs. 
Sellstrom et al. (2005) examined uptake of PBDEs by earthworms from sewage sludge- 
treated soils and reported that bioaccumulation factors decreased with molecular size. In 
2007, Voorspoels et al. analyzed PBDEs in tissues of the terrestrial red fox (Vulpes 
vulpes.) and found BDE209 was a dominant congener in the tissue profiles, representing 
70% of the total PBDEs.
While limited studies are available, burdens of the more brominated PBDE 
congeners have been observed to be remarkably higher in some predatory bird species. 
For example, a study of peregrine falcon eggs in Sweden detected BDE-209 in 18 of 21 
egg samples. The mean concentration values were 130 ng/g lipid in the southern
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population and 110 ng/g in the northern population (Lindberg et al., 2004). Another 
European study (Herzke et al., 2005) examined eggs from six species of Norwegian 
predatory birds. The species were evenly split between marine and terrestrial feeding 
specialists. Herzke et al. (2005) did not report BDE-209 in any of a total of 62 hatched 
eggs. However, BDE-183 was quantifiable only in peregrine falcon eggs and was 
consistent with the findings of Lindberg et al. (2004). Furthermore, Herzke et al., 2005 
documented species dependent PBDE congener patterns. Jaspers at al. (2006) evaluated 
oganohalogen body burdens in seven species of aquatic and terrestrial predatory birds 
from Belgium. . In this analysis BDE-209 and BDE-183 were only detected in the 
terrestrial birds.
Liang et al. (2008) identified BDE-209 as the dominant PBDE congener in 
foraging chicken hens from an electronic waste recycling area in southern China. This 
study showed peak BDE-209 levels in muscle tissue of 17,977 ng/g lipid wt. Chen et al. 
(2007) detected BDE-209 in birds of prey from northern China. Specifically, BDE-209 
was detected in 79.4% of the analyzed samples. Furthermore, it was the dominant 
congener in samples from some buzzards, scops owls, and long-eared owls. The highest 
liver levels of BDE-209 were detected in common kestrels, with a mean of 2,870 and 
maximum of 12,200 ng/g lipid weight. These values are much higher than those 
previously reported for BDE-209. The authors postulated that the dominance of the 
BDE-209 congener in these samples may be related to the large scale production, usage, 
and disposal (recycling of obsolete imported and domestic electronics) of Deca-BDE 
containing products in China.
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Luo et al. (2009) examined the presence of PBDEs in free-range domestic fowl 
within an electronic-waste recycling site in South China. Male and female chickens 
(<Gallus domesticus) and ducks (Anas platyrhynchos domesticus) were examined.
Samples of muscle and liver tissue from 51 birds were analyzed for PBDEs. The BDE- 
209 levels were higher in chicken (14-25 ng/g lipid wt.) than ducks (2.1-3.9 ng/g lipid 
wt.). While both species eat grain (9.7 ng/g dry wt.), the chickens also foraged for insects 
on land and may have been exposed to additional BDE-209 via consumption of soil and 
invertebrate prey.
In the USA, relationships between human population densities and PBDE 
congener patterns in wild birds have been identified. Potter et al., (2009) examined 
peregrine falcon eggs from the Chesapeake Bay region. BDE-209 levels were found to 
be significantly higher in birds nesting in densely populated urban areas. The levels of 
the octa and nona BDE congeners in these samples typically exceeded the BDE-209 
levels. While the reason for this is not fully understood, the authors postulated this was 
due to metabolic debromination of BDE-209 within the birds.
1.3: Toxicology and Pharmacology of PBDEs
The US EPA released a Toxicological Review of BDE-209 in June of 2008. This 
document is a comprehensive review of the available data on the toxicology of BDE-209. 
However, limited data were available for avian species. Therefore, the scope of this 
section includes a discussion of the toxicology of all PBDEs in a wide variety of species. 
Only dose-response relationships are discussed.
11
Traditional feeding studies that exposed mammals to BDE-209 dissolved in a 
solvent carrier show uptake rates of only 0.1-5% (Norris et al., 1975; El Dareer et al., 
1987). In feeding study of rats using radiolabeled 14C Deca-BDE (Norris et al., 1975) 
assimilation of the dose was low and complete elimination of the isotope was observed 
within two days. In contrast, retention of the Octa-BDE product was up to 40% within 
the rat. Norris et al. (1975) established a no observed effect level (NOEL) for Deca-BDE 
in rats of 8 mg/kg body weight per day in a 30 day dosing trial. Another study showed an 
uptake efficiency of 0.025-0.55% of Deca-BDE via dietary exposure over 14 days (El 
Dareer et al., 1987).
To mimic stomach contents and enhance the concentration of Deca-BDE 
accumulated, Morck et al. (2003) utilized an emulsion-based delivery vehicle, as is often 
used in drug delivery studies. It allows for increased suspension of large organic 
molecules in water. This approach may act as a more realistic delivery vehicle for dietary 
exposure of BDE-209 and permit heightened detection of candidate breakdown products. 
The emulsion delivery vehicle (Morck et al., 2003) for Deca-BDE resulted in a 10% or 
greater absorption of BDE-209 into the rat.
In a combined gavage and intravenous exposure study, Sandholm et al. (2003) 
showed an absorption rate of 26% in the rat. This study used an emulsion carrier similar 
to Morck et al. (2003). A total of 13 phenolic metabolic breakdown products were 
identified. This lends further support to the oxidative mechanism proposed by Morck et 
al. (2003).
In a feeding exposure and depuration study, Stapleton et al. (2004) observed no 
net accumulation of BDE-209 in juvenile carp (Cyprinus carpio). However, seven
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different compounds believed to be BDE-209 metabolites, were found in the exposed 
fish. This study was repeated in rainbow trout by Stapleton et al. (2006). BDE-202 was 
identified as the dominant breakdown congener. The uptake of BDE-209 into the fish 
was determined to be 3.2% based on the body burden of the hepta- through deca-BDEs. 
This evidence shows that determining the bioavailability of Deca-BDE is more complex 
than simply determining its body burden, as in some organisms degradation products 
such as partially debrominated PBDE congeners may predominate.
In a review of the developmental neurotoxicity of PBDEs (Costa and Giordano,
2007) discussed several dose response relationships including: spontaneous behavior 
(hyperactivity and decreased habituation) and disruption in learning and memory. It is 
believed that these effects are in large part due to disruption of the thyroxine system; 
specifically, by reducing circulating thyroxine (T4). Thyroxine is involved in 
metabolism and neural development. There are substantial structural similarities 
between T4 and PBDEs. Both share the same basic diphenyl ether structure. Both also 
contain halogen substitutions; iodines in the case of T4 and bromines in PBDEs. 
Bromine is more closely related in the periodic table to iodine than the chlorines present 
on, for example, PCBs. T4 is converted to T3 in the body where thyroid hormone 
activity is required, by removal of a meta-substituted iodine atom from the phenyl ring. 
(Figure 1.5).
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Figure 1.5: Structure of Thyroid Hormones
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I
(http://www.drharper.ca/new page 12.htm)
Endocrine receptor sites may exhibit cross reactivity .with chemicals that bear 
structurally similar to the intended hormone. It is possible to suppress (antagonist) or 
trigger (agonist) endocrine responses with synthetic chemicals. Antagonist molecules 
have the ability to block hormones or agonist molecules from receptor sites. This results 
in an inhibition of chemical signals. Agonist molecules bind with receptor sites and 
activate bio-chemical pathways. Molecular affinity constants measure the ratio of two 
chemicals bound together in solution versus the free forms of those chemicals in solution. 
These constants provide a quantitative tool for comparison when considering a variety of 
endocrine disrupting compounds (EDCs). Pathways other than the traditions 
agonist/antagonist actions exist. Protein transport can be equally important in delivering 
hormones and agonists/antagonists to active sites. The organism is not a static system 
and metabolic transformation pathways must also be considered. A more holistic view 
of the organism must also account for the probable mechanisms of toxic action for the 
given compound. A variety of studies have been conducted over the years to evaluate the 
toxicity of PBDEs. Acute toxicity of PBDEs appears low. Toxicity is generally thought
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to be greatest for congeners with four to six bromines and to be mediated by 
bioavailability. PBDEs have been shown to disrupt endocrine function, resulting in 
neurodevelopmental abnormalities, delayed puberty and reproductive issues (Zhou et al., 
2003; Stoker et al., 2005; Costa and Giordano 2007). The nature of PBDE toxicity is 
strikingly similar to that of the structurally-related PBBs and non-coplanar PCBs. Dose- 
dependent relationships between contaminants and toxic effects are paramount within 
toxicology and risk assessment science. Toxic compounds that bioaccumulate are 
especially important as this increases exposure. The summary of toxicology studies 
below focuses on observed dose-response relationships between PBDEs and effects.
In 2001, Zhou et al. examined the impacts of oral administration of Penta-BDE, 
Octa-BDE, and Deca-BDE commercial formulations on young female rats. Thyroid 
hormone levels and hepatic enzyme activities were measured following four days of 
exposure at a variety of dosages ranging from 0.3 mg/kg/day to 300 mg/kg/day. 
Thyroxine (T4) levels were depressed in the rats treated with Penta-BDE (DE-71) and 
Octa-BDE (DE-79). Significant decreases in T4 were observed with dosages of 10 
through 300 mg/kg/day. Thyroxine decreased by 80% in the treatment group with the 
highest Penta-BDE dose. Thyroxine levels were 70% lower than control in the group 
treated with the highest dose of Octa-BDE. Another important finding of this study was 
the dose dependent induction of hepatic phase I (CYP1A) and II (UGPDT- 
glucuronosyltransferase is a type of membrane protein residing within cells in the smooth 
endoplasmic reticulum) enzymes in the Penta-BDE and Octa-BDE treatment groups. 
Significant increases of hepatic enzymes were observed beginning with 30 mg/kg/day
15
dosage of both the Penta-BDE and the Octa-BDE. Deca-BDE did not cause any 
significant differences in any of the parameters measured in this study.
In a pubertal assay designed as a Tier 1 test for EDCs, male Wistar rats were 
orally exposed for three days to a commercial Penta-BDE mixture (Stoker et al., 2005).
A significant dose-dependent decrease was found in the weights of the ventral prostate 
(beginning at 30 mg/kg), seminal vesicle (beginning at 60 mg/kg), and Cowper’s gland 
(beginning at 120 mg/kg). This study also showed a delay in the onset of puberty in rat 
pups orally dosed with the Penta-BDE mixture at 60 and 120 mg/kg.
A group of researchers from Sweden headed by Henrik Viberg, have conducted 
numerous studies evaluating the impact of BDE-209 on mammalian brain development. 
Viberg et al. (2003) reported that BDE-209 can pass through the blood brain barrier in 
mice. Furthermore, the staggering of the doses throughout the neonatal period allowed 
for the identification of the most sensitive development stage for BDE-209 exposure, i.e. 
day 3 following birth for the mice. Neurobehavioral effects were only detected in the 
mice treated on this day. Additionally, the effects observed in these individuals became 
more extreme as the mice aged.
This study design was then repeated in rats (Viberg et al., 2005). Abnormal 
behavior was observed in young rats two months after being orally dosed with BDE-99. 
This study also showed a dose-dependent decrease in muscarinic cholinergic receptors in 
the same rats. The response was statistically significant beginning at the 16 mg/kg body 
weight dose. These findings mimic earlier work exposing mice to PCBs (Eriksson et al., 
1991). This study (Viberg et al., 2005) showed that BDE-99 can create persistent
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neurotoxic effects in mice if exposure occurs during a critical phase of neonatal 
development.
Another study was run, mimicking the methods of the previous two, to determine 
what the impact of BDE-209 would be on developing mammalian brains (Viberg et al., 
2007) The results of this study supported the earlier findings in mice. In addition, this 
study included a nicotine-induced behavior test. The key finding here was that nicotine 
exposure led to hyperactivity in control and low dose BDE209 treated mice. However, 
the animals exposed to the high dose of BDE-209 (21 mg/kg bw) showed hypoactivity 
following nicotine exposure. The implications of this finding are that the cholinergic 
system is a target for BDE-209-induced developmental neurotoxicity.
The same research group ran another study examining the impact of BDE-209 on 
mammalian brain development (Viberg et al, 2008). This time the brains of the animals 
were dissected into various components, including the cortex, the hippocampus, and the 
whole brain. The concentrations of three proteins were measured in the tissues seven 
days after exposure. There were significant differences between the mean concentrations 
of all three proteins in various parts of the brain. The three proteins investigated regulate 
different neuronal processes associated with survival, growth, and synaptogenesis. 
Building upon this work, a similar study was published in 2009 which investigated the 
impacts of BDE-209 on two additional neural proteins. Significant differences in protein 
levels were not detected for the two proteins examined (Viberg et al., 2009).
Viberg et a f  s 2008 study was criticized by flame retardant industry 
representatives (Hardy and Stedeford, 2008). Hardy and Stedeford criticized Viberg’s 
use of individual pups from the same litter as an experimental unit in the study discussed
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above. Hardy cites EPA methodologies that require toxicity studies control for the “litter 
effect” in mammalian studies. Hardy made a similar criticism of another BDE-209 rat 
exposure study by Van der Ven et al. (2008a). Van der Ven et al.’s rebuttal is relevant to 
the criticism of the Viberg et al. (2008b) study. Acknowledgement is made that there is a 
difference of opinion in the scientific community about the statistical methods that must 
be used when dosing pups in the neonatal period. Van der Ven goes on to note that the 
litter effect is of paramount importance when the dam is exposed and the pups are 
evaluated for effects. However, Viberg et al’s studies did not expose the dam. Instead 
male pups were exposed after birth in the neonatal period. In addition, Viberg et al 
maintained statistical power by using a minimum of three litters for each treatment group. 
So the individual pups were used as experimental units, but they do not ALL come from 
the same litter.
Van der Ven et al. (2008) conducted a 28 oral dose toxicity study of Deca-BDE in 
Wistar rats. This study replicated the gavage and emulsion method designed by Morck et 
al., (2003). The most sensitive effect in males was an increase in weight of the seminal 
vesicle, beginning at 0.2 mg/kg bw/day, and increased expression of CYP1A and CYP2B 
(0.5-0.7 mg/kg bw/day). In females, decreased activity of P450cl7 (CYP17), a key 
enzyme in the androgen synthesis pathway, was observed. The authors postulated that 
this result may indicate that Deca-BDE poses a reproductive health hazard.
1.4: Metabolism of BDE-209
In mammals BDE-209 is metabolized through an oxidative pathway to form a 
variety of hydroxylated PBDEs (EPA, 2008; Morck et al., 2003; Sandholm et al., 2003).
18
It is likely that this is mediated by an induced CYP1A reaction triggered by interaction of 
BDE-209 with the Arylhydrocarbon receptor (Ahr). The other possible mechanism for 
metabolism of BDE-209 is the reductive debromination of the molecule. For this to 
occur one of the bromine atoms is removed and replaced with a hydrogen atom. The 
products of this pathway would be lower brominated PBDE congeners; which are known 
to be more toxic than BDE-209. These would also be more strongly retained than 
hydroxylated PBDEs It appears that the reductive pathway occurs in fish (Stapleton et 
al., 2006). In adult birds, this may also be the case (Van den Steen et al., 2007).
Activation of thyroxine (T4->T3) requires the removal of an iodine atom from the 
5’ position of a diphenyl ether structure (see Figure 1.6). Chicken embryos show 5’- 
monodeiodinase activity (5’-MA) in both the liver and the brain. Valverde et al. (1993) 
reported that deiodination activity ceases in the brain around Day 15 of embryonic 
development. Valverde et al. made the observation that 5’-MA peaks at day 18-20 in 
liver of chicken embryos.
Figure 1.6: Activation of T4->T3
H2N
Type II 5'-monodeiodinase
In BDE-209, the diphenyl ether structure is fully brominated. Assuming 
dehalogenation of BDE-209 is facilitated by 5’-MA, logical degradates would be nona- 
and octa- PBDE congeners, lacking bromines at the position 5 carbons. These would bde 
BDE-207 and BDE-197. See figure 1.7. The argument can also be made that other 
deiodinases may be present with the ability to remove halogen atoms from all meta 
positions. The thought is that the active site of the enzyme might not be specific only to 
position 5, rather only specific to the meta postion of the ether linkage. This would create 
preferential formation of nona- and octa-BDEs with unsubstituted 3 and 5 position 
carbons. Van der Ven et al. (2008) reported production of BDE-207 in the livers of 
Wistar rats exposed to BDE209. The ratio of BDE207 to BDE209 was used to track 
biotransformation over their 28 study period.
Debromination of BDE-209 in adult starlings was recently investigated by Van 
den Steen et al. (2007), using silastic implants to deliver BDE-209 into the blood stream 
of starlings. At the conclusion of that study the BDE-209 concentrations in the tissues of 
the control birds were below the limit of quantitation of 5.6 ng/g lw (muscle) and 2.9 ng/g
Figure 1.7: BDE-207 and BDE-197
Br BDE-207
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lw (liver). In the exposed birds the muscle tissue concentrations of BDE-209 were about 
twice that of the liver concentrations (430 ng/g lw and 237 ng/g lw respectively.) They 
postulated that the liver possessed greater metabolic activity than muscle, reducing 
associated BDE209 burdens. This was supported by the observation that the relative 
concentrations of the nona-BDEs were greater in the liver than the muscle tissue. This 
study showed that, while adult birds are capable of debrominating BDE-209, the 
chemical still accumulated in avian tissues. Eggs have been observed to contain both 
BDE-209 and apparent debromination products.
1.5: Egg Exposure
Egg injection bioassays have been developed and tested since the 1960s. A 
variety of methods exist to deliver compounds to a developing avian embryo. Many 
researchers have explored exposing the outer egg shell to petroleum products and 
insecticides. There are two main distinctions between egg injection methodologies. 
Namely, those that target the air cell of the embryo (i.e., the space between the eggshell 
and the outer membrane of the embryo) and those that target the yolk.
Some of the earliest yolk injection studies were designed to evaluate the efficacy 
of this test in determining comparative toxicity of different compounds on avian growth 
and development (Walker 1967, McLaughlin et al. 1963). In this sense, the findings of 
Walker (1967) findings were definitive on the matter. “Chemicals and mixtures of 
various types injected into the yolks of fertile eggs moved and reacted in different ways, 
depending upon their densities and individual properties”. Clearly, results of tests with
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different modes of toxicant delivery, and therefore different organismal exposures, should 
be treated with caution.
Walker’s findings remain crucial in understanding the dynamics of yolk 
injections. Further investigations have been conducted to compare the impact of a given 
toxicant when injected into either the yolk or the air cell of a chicken embryo. Henshel et 
al., (1997) published a study comparing 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
toxicity in developing chicken embryos by these two injection methods. Findings 
showed the embryo was more sensitive to TCDD when injected into the yolk (LD50 =
122 pg/egg) than the aircell (LD50 = 297 pg/egg). Henshel’s findings are the opposite of 
Gebhardt and van Logten (1968). Gebhardt and van Logten tested the comparative 
toxicity of a dithiocarbamate in yolk versus air cell injections to the chicken embryo.
They reported that for these toxicants, the embryos were more sensitive to the thiram 
injected into the aircell (LD50 = 1.1 jog), rather than into the yolk (LD50 =18 pg). In 
order to understand these inconsistencies, Walker’s findings must be revisited. Henshel 
provides a compelling discussion of these results within the context of Walker’s findings.
Transfer of contaminants from hens to eggs occurs as a continuous process as the 
egg is created within the bird. Over time the mother lays down nutrient layers in the yolk 
for the developing embryo to consume throughout the development process. There is an 
order and structure to the creation of the ovum. Walker (1967) documented the behavior 
of a variety of chemicals when injected into the yolk of the developing chicken egg.
Using various dyes, Walker (1967) tracked the movement and disposition of various 
chemicals in chicken yolks. Oils were found to not mix well at all with the yolks, rather 
they rose to the top of the yolk as a “single bubble”. Walker reported low mortality for
22
vegetable oil yolk injections but high mortality for other compounds that behaved 
similarly; rising as a single bubble when injected to the yolk. This is likely due to the 
close proximity of the “bubble” with the blastodisc, which also rises in the yolk and 
rotates as the eggs are turned throughout incubation
Henshel’s reasoning illustrates many of the facets of the yolk injection exposure 
approach. The nature of the carrier may define the exposure, as much as, if not more than 
the nature of the toxicant itself. Henshel calls for the evaluation of results within the 
context of the injection site and the impact it may play on both physiological and physical 
processes occurring within the egg. Figure 1.8 below is Henshel’s Appendix. It presents 
a matrix of the advantages and disadvantages inherent in each of the two methods.
Figure 1.8: Appendix from Henshel et. al. 1997 p 732
Air cell Yolk
Benefits 1. Able to inject throughout incubation. 1. Able to inject a larger amount o f  chemical 
without causing nonspecific embryo mortality.
2. Applied directly onto embryo. This 
is especially useful if  the chemical is 
readily taken up by the embryo.
2. Oil or emulsion-injected material stays near 
the top o f  the yolk, readily accessible to the 
embryo.
3. Vehicle is not as critical as for the 
yolk, although it may define the 
maximum injection volume
3. Material taken up by the embryo by 
“natural” processes during yolk absorption, 
and distributed with all nutrients through the 
embryo
Drawbacks 1. Might inject into albumin, and lose 
early embryo exposure. (Albumin is 
used by the embryo in the latter half o f  
the incubation period.) This w ill also 
cause a decreased apparent toxicity for 
chemicals that also affect early 
embryos.
1. Not as good for later embryo injections, as 
one is more likely to damage the embryos or 
the vitelline vasculature and cause potential 
hemorrhage or abnormal growth.
2. If very small quantity is injected, it is 
possible that the embryos may not be 
exposed to the substance immediately 
because a very small amount o f  
substance could move around the 
embryo rather than across the embryo.
2. Oil or emulsion tends to be more 
concentrated and is not diluted by entire yolk, 
so embryo is exposed to higher concentrations 
earlier in incubations than if  chemical mixed 
well with yolk.
3. Maximum recommended total 
injection volumes to avoid vehicle- 
related embryo mortality: 50 pi for oil- 
based; 100 pi for water-based.
3. Some diluents or solvents interact with yolk 
(e.g. propylene glycol and formaldehyde), and 
therefore are not accessible to the embryo, 
producing falsely high medial lethal doses 
(LD50s) and median effective doses (ED50s).
23
There are several reasons for selecting the yolk over the air-cell injection method 
with regards to Deca-BDE: 1) Carriers commonly used in the air-cell injections of the 
Penta- and Octa-BDEs do not solubilize Deca-BDE well 2) While the air-cell is within 
the eggshell it is separated from the embryo by a membrane. This means that materials 
injected into the air cell must first pass through this before contacting the embryo. By 
injecting material directly into the yolk of the egg, the food source for the embryo, the 
material is immediately available (See Figure 1.9).
Figure 1.9: Egg Yolk Injection
Y o lk
A ir C e ll
Maternal transfer of nutrients into the egg is done in a structured manner; 
nutrients are laid down in layers. Obviously, it is impossible to replicate the exact 
internal structure and distribution of a contaminant as transferred from hen to egg, 
without conducting a feeding study of the hens. Yolk-injection was chosen for this study 
because it allowed the preservation of a closed system within the egg. However, the 
author desired to have the distribution of yolk-injected BDE-209 similar to what occurs 
from maternal transfer. The findings of Walker (1967) are definitive on the behavior of
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various chemicals when injected into the yolk-sac of chicken eggs. Walker determined 
that injection of water soluble compounds mixed well with yolk, while oils tended to 
move “en masse” with no sign of mixing. An emulsion formulation was chosen because 
of the high water content, 78% (w/w) for the emulsion used in these studies. An 
emulsion by definition contains oils. Therefore, it is likely that the yolk-injected 
material was not dispersed evenly throughout the entire yolk. It is likely that the 
emulsion spread somewhat from the original “bubble”. It is also likely, that some of the 
original “bubble” remained cohesive. In this case, the embryos would have experienced 
greater exposure as the bubble rotated with the embryo inside the eggs throughout 
incubation.
1.6: Purpose
The purpose of this study was to examine the biological partitioning of BDE-209, 
the major congener of Deca-BDE, in an avian embryo. In the US, the use of Deca-BDE 
is currently unregulated at the federal level, although restrictions on some specific 
applications are in place in several states4. Restrictions are also under consideration in 
Canada and Deca-BDE has been banned in new products in the EU. It remains in 
extensive use around the globe as a flame retardant additive in numerous consumer 
products. The EPA TRI indicates substantial Deca-BDE releases directly to the 
environment and through wastewater treatment plants. Releases directly from in-use 
products also occur, as evidenced by its presence at mg/kg levels in indoor dust. 
Numerous studies have detected BDE-209 in the environment, and it is often the most 
abundant congener in abiotic media such as sewage sludge, soil and airborne particulates.
4 (http://www.bsef.com/regulation/north-america/deca-bde-3/)
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However, until recently, it was not reported in biota. Rather, the constituent congeners of 
Penta-BDE (BDE-47, 99, 100, 154 and 154) were typically reported, especially in aquatic 
organisms and on occasion at concentrations in excess of 10 mg/kg (lw). Previous 
studies have shown that BDE-209 is environmentally persistent and widely distributed. 
Based on its large molecular size, strong sorption to particles and low water and lipid 
solubility it was originally believed to pose a minimal environmental hazard. This 
supposition was supported by studies of aquatic species, which showed almost no 
bioaccumulation. However, substantial burdens of BDE-209 have more recently been 
observed in some terrestrial birds. In addition, nona- and octa-brominated congeners, 
thought to be derived from BDE-209, have also been reported in raptors and their eggs. 
Similar congeners have been observed in fish near large BDE-209 point sources (La 
Guardia et al, 2007), as well in laboratory feeding studies (Stapleton et al, 2004). These 
indicate that a fuller understanding of routes of exposure is critical to evaluate the true 
toxicological ramifications of continued Deca-BDE use. . Much lower BDE-209 levels 
have been observed in terrestrial mammals than in raptors. Bird eggs are a widely used 
environmental matrix to monitor contaminant levels. The toxicology literature indicates 
that BDE-209 is rapidly excreted by some mammals (Norris et al. 1975 and Morck et al. 
2003). Van den Steen et al. (2007) was the first to demonstrate debromination of BDE- 
209 in birds in the course of an in-laboratory exposure. There has been limited work to 
date examining the toxicological impacts of BDE-209 on developing avian embryos.
This is especially relevant as BDE-209 and less brominated congeners, believed to be 
BDE-209 degradates, are known to accumulate in terrestrial birds and their eggs.
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It is uncertain whether these metabolic byproducts are produced in-ovo or are pre­
existing in the resources transferred from the hen to the egg. The lower brominated 
PBDEs have typically been reported to have higher toxicities and bioaccumulative 
potentials than BDE-209. Therefore, if BDE-209 is debrominated in the mother hen and 
then transferred to the eggs, there is the potential for enhanced toxicity at the beginning 
of embryonic development. If BDE-209 is degraded in the embryo to more toxic 
metabolites then toxicity may increase throughout embryonic development. This study is 
designed to address the latter question.
Tissue distribution is important to consider as well, as chemicals may interfere 
with the function of specific organs or biochemical pathways. For example, numerous 
studies (Viberg et al. 2003, 2005, 2007, and 2008 amongst others) have shown that BDE- 
209 is developmentally neurotoxic to mammals during the brain growth spurt on day 3 of 
life. This study will assess the disposition and acute toxicity of BDE-209, and possible 
partial debromination products, in the developing embryo and various critical organs.
Chickens (Gallus gallus) show high sensitivity to toxicants that bind with the Ahr, 
and relatively low sensitivity to toxicants which cause egg-shell thinning such as DDT. 
The chicken was chosen as an avian model for this study as it is: readily available, easy to 
maintain in the laboratory and is a major food source for humans. Substantial levels of 
BDE-209 and assumed degradates have been reported in some terrestrial avian species, 
including domestic chickens near point sources of Deca-BDE such as electronic recycling 
sites, as well as in feral raptors (Liang et al. 2009). The current prevailing hypothesis is 
that BDE-209 (the major component of the Deca-BDE commercial product) is more 
prevalent in terrestrial than aquatic organisms. Concentrations of BDE-209 in some
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terrestrial birds (130-2000 ng/g lipid) have been observed to exceed by over an order of 
magnitude those reported in mammals (<41 pg/kg lipid) (Lindberg et al., 2004; Chen et 
al., 2007; Christensen et al., 2005). This study will examine the distribution of BDE-209 
following injection into the yolk-sac of chicken embryos. The egg yolk injection 
methodology is also expected to maximize the absorbed concentration of BDE-209, 
allowing for an increased likelihood of detecting it and any related debromination 
products.
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MATERIALS AND METHODS
M.l: Dosing Formulation
An emulsified formulation of BDE-209 was developed for yolk injection into 
chicken eggs. The basis for the formulation came from a study (Morck et al., 2003) run 
in mammals where the exposure vehicle was designed to better disperse the dose of this 
extremely hydrophobic PBDE and mimic stomach contents. The emulsification agents 
used were Lptrol® micro 127 MP and Phospholipone® 90G from BASF Corp. (Florham, 
NJ) and Lipoid LLC (Newark, NJ), respectively. Decabromodiphenyl ether (BDE-209) 
was ordered from Wellington Labs (Guelph, Ontario, Canada). Preliminary work was 
done with commercial preparations of Deca-BDE. However, a highly purified (>98%) 
BDE-209 standard was required for this study as a major interest was the potential for 
biotransformation to less-brominated congeners. The BDE-209 was first dissolved in a 
2:1 v/v toluene and diethyl ether solvent mixture. This required the use of a probe 
sonicator (type) for 30 minutes. The BDE-209 solution (volume) was then added to an 
emulsion vehicle base composed of a mixture of Lptrol® micro 127 MP and 
Phospholipone® 90G in a ratio of 34:16 in water. The remaining water was then added 
to the solution drop-wise while mixing. The final step was to evaporate off the solvents 
using a purified N 2 stream. A total of five treatments were developed; four different
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doses of BDE-209 and an emulsion vehicle. The nominal concentrations of the doses 
were 80 pg/egg, 40 pg/egg, 20 pg/egg, and 5 pg/egg. The highest dose (80 |Lig/egg) was 
administered in 100 (al injections. The rest of the doses were administered in 50 pi 
injections. Therefore the high dose emulsion with a concentration of 800 |ag/ml of 
emulsion, was the same emulsion used in the 80 |ag/egg and 40 |ag/egg treatment groups. 
This is discussed in more detail below.
M.2: Dose Verification
Nominal concentrations of the BDE-209 emulsions were verified analytically 
following the methods of LaGuardia, 2008. The extraction method was designed by the 
author with assistance from Mr. LaGuardia. The high, medium, low and vehicle 
treatment emulsions were subjected to liquid/liquid extraction using dichloromethane 
(DCM) and quantification by gas chromatography and mass spectrometry (GC/MS) in 
the electron capture negative ionization (ECNI) mode. Briefly, one ml of each emulsion 
was first diluted with 100 ml of DI H2 O before being subjected to three 5 ml extractions 
with DCM in a separatory funnel. Each wash with DCM was shaken for five minutes 
before allowing the layers to separate and collection of the organic layer. The organic 
layers were collected in an appropriate volumetric flask for dilution into the range of the 
calibration curve from 50 ng/ml to 5000 ng/ml. The extract of 1 ml of the high dose 
emulsion was diluted with hexane into a 500 ml volumetric flask. An aliquot of that 
dilution was then analyzed by GC/MS. The ions of interest 79 and 81 (m/z) were 
monitored throughout the whole run and used to integrate and quantify BDE-209. The 
ion 486 was used to confirm BDE-209. The expected concentration from this 500-fold
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dilution was 1600 ng BDE-209 per ml. The extract of 1 ml of the medium dose emulsion 
was diluted with hexane in a 250 ml volumetric flask. An aliquot of that dilution was 
then analyzed by GC/MS. The expected concentration from this 250-fold was also 1600 
ng BDE-209 per ml. The extract of 1 ml of the low dose emulsion was diluted with 
hexane into a 100 ml volumetric flask. An aliquot of that dilution was then analyzed by 
GC/MS. The expected concentration from this 100-fold dilution was 983 ng BDE-209 
per ml.
The samples were then spiked with 300 ng of decachlorodiphenyl ether (DCDE; 
CAS# 3170-30-2) as an internal standard and analyzed by GC/MS in the NCI mode. 
Congener peak areas generated were compared to that of the internal standard added to 
the extract. Response factors were determined using authentic PBDE standards from 
AccuStandard (New Haven, CT, USA) and Cambridge Isotope Laboratories (Andover, 
MA, USA).
Instrumental analysis followed that was described previously by LaGuardia et al. 
(2006) and Chen et al. (2008). Final extracts were analyzed by GC (6890N, Agilent 
Tech., Palo Alto, CA) with MS detection (JMS-GC Mate II, JEOL, Peabody, MA). Ion 
fragments were produced in the ECNI mode using methane (99.99%) as the reagent gas. 
Injections (1 pi) were made into the splitless injector equipped with a 1 mm i.d. glass 
liner. A 15 m DB-5HT column (J&W Scientific, Agilent Technologies, 0.25 mm ID, 0.1 
pm stationary phase thickness) was installed in the GC. Helium was used as the GC 
carrier gas at an initial pressure of 50 psi. The injection technique used, “pressure pulse 
split-splitless”, shows minimal thermal degradation of BDE-209 (LaGuardia, 2008). 
Initial column temperature was 90°C and held for 4 minutes. Temperature was then
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increased to 150°C at 30°C/min, then 10°C/min to 300°C and held for 7 minutes. The 
column temperature was then increased to 350°C for 5 minutes as a bake out procedure.
M.3: Eggs and incubations
All egg incubation methods followed those from McKeman et al. (2009). Dr. 
McKeman was instrumental in the completion of this work, and all experiments at 
Patuxent (PWRC) were run under her scrutiny. Preliminary work with the emulsion 
vehicle in chicken embryos was conducted at VIMS (Gloucester Point, VA, USA). All 
of the procedures involving animals were approved by the Institutional Care and Use 
Committees of the College of William and Mary and PWRC. CBT Farms (Chestertown, 
MD, USA) supplied the fertile white leghorn chicken (<Gallus gallus) eggs used in studies 
employing viable embryos. All of the eggs were washed in a 40°C 1% Betadine® 
solution (Purdue, Wilson, NC, USA) upon arrival. Each egg was then weighed and 
labeled with a number 2 graphite pencil. The eggs were then stored in a cooler at 13°C 
for up to 3 d. Eggs were allowed to equilibrate to room temperature before placement 
into incubators. Eggs were artificially incubated (Kuhl Incubator Company, Flemington, 
NJ) in trays that rotated eggs horizontally (180 degrees per hour). Incubators were set at 
37.6°C, as is recommended for chicken eggs (Henshel et al., 1997). The relative 
humidity within the incubator was originally set at 40%. Egg weights were monitored 
every 3 to 4 days throughout incubation. The relative humidity was adjusted so the mean 
egg weight loss at the end of incubation was 14 to 16%. Eggs were candled at the time of 
weighing to confirm viability. Any unfertilized or dead eggs were removed.
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M.4: Dose Administration
These methods were adapted from Quinn et al. (2008) for species differences 
between Japanese quail and chickens. Prior to injection, the blunt end of each egg was 
cleaned with an alcohol swab and was penetrated using a drill (Dremel, Racine, WI 
USA). Two different injection volumes were used in this study; 50 pL and 100 pL. This 
is why the various doses were all delivered on a per egg basis. The volume of the yolk- 
injected dose and control treatments were kept constant in all trials. The doses were 
administered to the developing embryos by injection into the yolk-sac using a Hamilton 
syringe with a 22 gauge needle. To determine the proper depth to insert the needle, eggs 
were measured lengthwise. The average length was then divided by 2 to determine the 
center of the egg. A pipette tip was then measured and placed over the tip of the needle 
to act as a stop. This allowed the injection to target the center of the egg every time. 
Preliminary work was conducted with water and dye to confirm the location of the 
injection within the embryo. Separate syringes and needles were used for the vehicle and 
treatment groups to prevent contamination. The hole in the egg was then sealed with 
ethylene vinyl acetate adhesive using a hot glue gun. All eggs were kept out of the 
incubator for an equivalent 30 minutes. Eggs were then placed in trays and positioned 
horizontally into the incubator.
M.5: Monitoring Survival and Sample Collections
The methods followed have been described by McKeman et. al.(2009), except for 
a modest change in the sample collection timing. Embryo survival was monitored at 3 to 
4 d intervals by candling or with a viability detection instrument (Buddy, Vetronic,
33
Torquay, UK). The Buddy instrument detects electrical impulses from both the beating 
heart of the embryo and any motor movements occurring within the egg. Embryos that 
died during development were removed from the incubator and stored in the freezer for 
chemical analysis. The endpoint of this study was the 20th day of incubation, as this is 
the last day before pipping and followed the peak in liver enzymatic activity. As the goal 
was to evaluate in ovo fate of the BDE-209, it was imperative that the chicks were 
sampled before they left the closed system of the egg. On Day 19 or 20 the chicks were 
removed from the eggshells, weighed, and examined for evidence of edema and 
teratogenicity (e.g. eye, foot or bill deformities). The birds were then sacrificed by 
decapitation. The liver, heart, brain and remaining yolk-sac were promptly removed and 
weighed.
M.6: Trial 1: Evaluation of emulsion vehicle-induced embryonic mortality, VIMS, 
December 2007
A total of 20 eggs from CBT Farms in Chestertown MD were received on 
12/4/2007. The eggs were candled. One egg was cracked and therefore discarded. The 
eggs were then placed in an incubator and maintained at 37°C. Humidity levels were not 
monitored, but water was regularly added every few days to the lower tray of the 
incubator. At Day 4 all the eggs were candled again. Six of the 19 eggs were not viable 
at Day 4 and were discarded. The remaining 13 eggs were randomly assigned to one of 
three treatment groups; uninjected (n = 4), deionized water (DI) water injected (n = 4), or 
emulsion vehicle injected (n = 5). Assignment was done randomly by rolling a die, two 
numbers were selected for each treatment group. The emulsion injection volume used
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was 100 fiL. Incubation was continued through Day 19. The remaining embryos were 
then removed from their shells, sacrificed and necropsies conducted. Tissue weights 
were recorded for the yolk, liver, and brain.
M.7: Trial 2: Evaluation of emulsion-induced embryonic mortality, VIMS, 
February 2008
A total of 47 eggs from CBT Farms (Chestertown MD) were incubated beginning 
on 2/15/2008. The eggs were then placed in an incubator and incubated at 37°C. 
Humidity levels were not monitored, but water was regularly added every few days to the 
lower tray of the incubator. At Day 4 all the eggs were candled again. Two of the 47 
eggs were not viable at Day 4 and were discarded. The remaining 45 eggs were 
randomly assigned to one of three treatment groups; uninjected (n = 15), sham-injected (n 
= 15), or vehicle injected (n = 15). The “sham” injections mimicked the emulsion vehicle 
injections, in that the needle was pushed into the yolk. The only difference between the 
“sham” and vehicle emulsions is that no liquid was delivered to the yolk in the sham 
injections. Treatment assignment was done by tossing a die. The injection volume used 
was 100 pL. At Day 19, the embryos were removed from their shells, sacrificed and 
tissue weights determined.
M.8: Trial 3: Testing the effects of a single BDE-209 dose on embryonic mortality, 
Patuxent Wildlife Research Center, June 2008
Beginning on June 11, 2008 a trial of 198 eggs was run. Initiation and 
termination of the trial was staggered over a three day period. This resulted in three
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replicates of each treatment group. On Day 4 of incubation all the eggs were randomly 
assigned to one of three treatment groups. The treatment groups in this trial were 
uninjected (n = 26), vehicle injected (n = 80), and BDE-209 injected at 80 pg/egg dose (n 
= 79.) The injection volume in this trial was 100 pL. Mortality and moisture weight loss 
were monitored throughout the incubation period. At Day 19, the embryos were removed 
from their shells, sacrificed and necropsied.
M.9: Trial 4: Testing the effect of multiple doses of BDE-209 on embryonic 
mortality, Patuxent Wildlife Research Center, July 2008
Multiple doses of BDE-209 were injected into chicken yolks. The injection 
volume for this trial was 50 pL. The high dose was 40 pg/egg or 800 pg/ml of emulsion 
(n = 47). The middle dose was 20 pg/egg or 400 ug/ml of emulsion (n = 49). The low 
dose was 5 pg/ egg or 100 pg/ml of emulsion (n = 43). A total of 30 eggs were also run 
as uninjected controls. Again the initiation and termination of this trial was staggered 
over a three day period. This resulted in three replicates of all five treatments. Mortality 
and moisture weight loss were monitored throughout the incubation period.
On day 19 the embryos were sacrificed by decapitation. The birds in the middle 
dose and vehicle treatment groups were necropsied. Five compartments were examined; 
liver, heart, brain, yolk, and remaining carcass. These compartments were all weighed 
prior to being collected in solvent-rinsed glass jars for further analysis. The tissues and 
the yolks from the individual birds were pooled together. Four birds were pooled per 
composite sample. So, one set of the five tissue samples contained the tissue from four 
individual birds.
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M.10: Experiment 2: Absorption and distribution of yolk-sac administered BDE- 
209
For the chemical distribution aspect of the study, samples were collected from 
only the Middle dose (20pg/egg) and Vehicle treatment groups from Trial 4. The Middle 
dose treatment group was selected because of the sample size that survived through to the 
end of incubation. Due to the small weight of the tissues collected and the expected low 
attendant amounts of analyte present, the samples were pooled. Birds within a treatment 
group (n = 32 per group) were selected at random for pooling. Four birds were selected 
from each treatment for each pool. In an effort to control the total number of samples and 
provide statistical meaning, the number of birds collected from each group was 
predetermined to be 32. Each pool of four birds resulted in five pooled samples total, 
including: livers, hearts, brains, pooled yolks, and carcasses. The total sample size for 
each compartment within each treatment was eight. The birds were necropsied 
sequentially and the organs were collected in solvent rinsed glass jars.
All tissue samples were subjected to chemical analysis as described by LaGuardia 
et al. (2007) and Hale et al. (2001). The first step was freeze-drying for a period of 48 
hours (Dura Top, FTS Systems, Stony Ridge NY). Tissue samples and sodium sulfate 
blanks were spiked with a surrogate standard consisting of 1000 ng each of PCB-204 and 
BDE-166. Dried samples were extracted using enhanced solvent extraction (Dionex 
ASE 200, Sunnyvale CA). Two 5-min. extractions were performed per sample with 
DCM at 100°C and 1000 psi. Gravimetric analysis of a 10% subsample of the extract 
was conducted to determine DCM soluble lipids. Next, size exclusion chromatography
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(SEC) was performed to remove the large molecular weight biogenic lipids from the 
analytes of interest (Envirosep-ABC, 350 x 21.1 mm column; Phenomenex, Torrance, 
CA). The final purification step was conducted using a 2 g, silica gel, solid phase 
extraction column (Isolute, International Sorbent Technology, UK). The first fraction 
was eluted using 3 ml of hexane and discarded. The second fraction (S2), containing the 
halogenated compounds of interest, was eluted using 10 ml of a 90:10 v/v hexane/DCM 
solvent mixture and retained. A third fraction (S3) composed of an additional 5 ml of the 
90:10 hexane/DCM mixture was also eluted and collected. The columns were then eluted 
with 9 ml of acetone (S4) to remove any remaining potential analytes of interest. The S2 
fractions were reduced to near dryness under purified nitrogen and exchanged to hexane. 
These were then spiked with 300 ng of the internal standard DCDE. Instrumental 
analysis followed that was described previously for the dose verification portion of this 
study.
M .ll: Data Analysis and Mass Balance
A major goal of this study was to determine the fate and behavior of BDE-209 in 
the developing chicken embryo. To best accomplish this, a mass balance approach was 
applied. The mean concentration values of the different tissue samples were multiplied 
by the total tissue weights. The sum of these values should equal the original treatment 
dose. If the mass measured is less than the amount dosed then it is likely that not all of 
the BDE-209 made it through the analytical process, there was biotransformation of the 
BDE-209 into other chemicals or errors exist in the measurement of dosage of tissue 
residues. Use of pooled tissue samples will also result in some error.
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It should be noted that the high lipid content of the yolk and carcass tissues may 
also create matrix interferences in the MS detector. The extraction and cleanup methods 
discussed below were optimized to minimize any matrix induced signal interference.
M.12: QA/QC and Method Development
The samples collected from trial four were chemically analyzed for BDE-209 and 
potential PBDE-debromination products. Originally all 80 samples (5 tissues with 8 
replicates in two treatments groups) were freeze dried in preparation for organic 
extraction. Preliminary work was done with the yolk and carcass samples from the 
vehicle treatment group, as there was ample sample available from these two tissue 
compartments. The method originally tested is described by LaGuardia et al. (2006) and 
Hale et al. (2001) and is used routinely on fish samples to quantify PBDEs and other 
organic contaminants. Unfortunately, employing this method with the chicken egg 
matrix resulted in GC/MS interference issues. In spike recovery studies, the BDE-209 
signal in the yolk and carcass matrices was amplified 1.5 to 2 times that of the standards. 
This was attributed to excess biogenic material in the final purified extract. Therefore, 
modifications to eliminate more of this material from the samples were required.
The solid-phase extraction (SPE) step was the final step for the elimination of co­
extracted biogenics. Hence, various column elution options were examined. A weaker 
solvent regime would likely elute off less material. Therefore, initially the utility of 
100% hexane was examined. BDE-209 was eluted, but required a high volume (15 ml) 
of solvent. Next, a solvent regime of 10% DCM and 90% hexane was next tested. Three 
replicates were run. The columns were prepped with 5 ml of 100% hexane. The SPE
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columns were spiked with 1000 ng BDE-209, 480 ng PCB-204, and 480 ng BDE-166. 
The first fraction was eluted with 3 ml of hexane and discarded. The second (S2) fraction 
consisted of 8 ml of 10% DCM 90% hexane. This was collected, reduced to < 1ml and 
spiked with 300 ng DCDE before GC/MS analysis. The third (S2_A) fraction consisted 
of an additional 3 ml of 10% DCM. The fourth and fifth fractions (S2_B and S2_C, 
respectively), were also 3 ml of 10% DCM. These were also reduced to <lml and spiked 
with 300 ng of DCDE as an internal standard.
Based on the data from the spiked column trial discussed above, a spike recovery 
test was run using locally-bought eggs. A dozen large white eggs (nonviable) were 
purchased from a commercial grocery chain store (Food Lion, Yorktown, VA, USA).
The yolks were collected from six eggs, pooled, homogenized and freeze dried. For the 
other six eggs the yolks and the egg whites were combined, homogenized and freeze 
dried. Three replicates of each matrix, as well as three blanks consisting of sodium 
sulfate were processed. Each sample was then spiked with 1ml of a composite standard 
containing 2000 ng/ml BDE -47, -99, -154,-183, and -209. as well as 820 ng/ml of PCB- 
204 and BDE-166. The samples then underwent extraction on the ASE (Dionex, 
Sunnyvale, CA, USA) followed by lipid analysis and size exclusion on the HPLC. Only 
56.3% of the original sample material makes it through to the SPE step; due to 
mechanism for filling the injection loop. The previously described SPE column study 
showed that 8 ml of 10% DCM was insufficient to elute all BDE-209 from the silica gel. 
In the spiked matrix study, 10 ml of the 10% DCM was used to elute the S2 fraction.
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Procedural blanks consisting of sodium sulfate were run with every batch of ten 
samples. These were spiked with the surrogate standard (BDE-166) and monitored for 
possible BDE-209 contamination.
M.13: Statistical Analysis 
Contingency Analysis , Chi-Squared)
The mortality data for each trial were organized into a contingency table; where 
the columns represent survival or death and the rows represent the various treatment 
groups.
Table M.l: Contingency Table, Observed Values
Observed
Survive Dead Total
Vehicle X y x+y
Deca w z w+z
Total x+w y+z ... x+y+w+z
The row totals are multiplied by the column totals and divided by the overall total 
to calculate expected values.
Table M.2: Contingency Table, Expected Values
Survive Dead Total
Vehicle (x + y)  * (x + w) 
x + y + w + z
(x + y ) * ( y  + z) 
x + y + w + z
x+y
Deca (w + z) * (x + w) 
x + y + w + z
(w + z) * (y + z) 
x + y + w + z
w+z
Total x + w y+z x+y+w+z
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The final step is to calculate and total the differences between the observed and 
expected values using the following formula.
2 = y { O - E)2
*  Lu e
df = (r-l)*(c-l) 
r = # of rows, c = # of columns 
The null hypothesis for this test is that the treatments (rows) have no impact on 
the probability of mortality (columns). The alternative hypothesis is that the rows 
(treatments) increase the probability of one of the columns (mortality). The % value and 
the degrees of freedom (df) were input into Microsoft Excel to calculate the 
corresponding p-value from the probability density function.
Acute Toxicity ~ Calculating the LD50
The Median Lethal Dose (LD50) is a metric often used in toxicology and risk 
assessment. The methods used here came directly from the 1995 reference “Quantitative 
Methods in Aquatic Ecotoxicology” by Michael C. Newman. In order to accurately 
calculate the LD50 for a given compound, and method of exposure, data for multiple 
doses are required. Furthermore, the data set must include at least one example of a 
partial kill; i.e. mortality other than 0% or 100%. The first step in determining the LD50 
for a given set of data is to determine the distribution of the data. This means trying to 
determine which model (Normal, Logistic, or Weibull) the data distribution best fits. 
Normally distributed data form a bell curve centered on the mean value of a given 
parameter in a population. Logistically distributions are similar to normal data, except
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the bell shows greater kurtosis.. The Weibull distribution is more exponential in 
appearance.
In conducting the LD50 analysis, the data distribution plays a key role in 
determining the appropriateness or “best fit” of the method used. For example, if the data 
are normally distributed, then Probit analysis is most appropriate. If the data are 
logistically distributed then Logit analysis is a better tool. Finally, if the data follow a 
Wiebull distribution then the Gompertz model is the most appropriate. Determination of 
the distribution of the data and selection of the appropriate model can be done by 
comparing the Pearson Chi-Square value for each analysis. The Pearson Chi Square 
value is provided by the SAS program as a measure of “goodness of fit.” The smaller the 
value of the Pearson Chi-Square value the better the fit of the data to the assumed 
distribution and corresponding model. The distribution of data points is an important 
consideration when fitting models It is widely accepted that the internal areas of the 
cumulative density function (CDF) are most accurate. This is one reason why the LD50 
is used so often. The accuracy of the models is tested in the external realms of the CDFs 
or the tails. Hence, values for LD5 (lethal dose of 5% of the population) and LD99 
(lethal dose 99% of the population) are not used as widely. These values can easily be 
determined once a model has been fit to the data. This is where the distribution of the 
data becomes important. The assumptions made at the beginning of the process have an 
impact on the results, especially at the extremes. This is why the Pearson Chi-Squared 
value is important in understanding the distribution of the data and hence the selection of 
the most accurate model.
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The data from the last two trials were pooled to develop a dose response curve. 
Again, the method here follows the 1995 Newman text. These data were then input into 
S AS 9 and used to estimate a model of mortality that accounts for the toxicity of the 
emulsion itself and not the BDE-209. The data were first fit to a Probit, then a Logit and 
finally a Gompertz model. The model with the best fit was identified by the smallest 
value of the Pearson Chi-Square Value for the “Goodness of Fit” test. This model was 
then used to subtract out the mortality rate of the emulsion carrier. The median lethal 
dose of BDE-209 yolk-injected into chicken embryos was then calculated. This is a 
toxicological metric often used in risk assessment and policy decision making.
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RESULTS 
R.1: Trial 1: Testing the Effect of Egg Injection (Emulsion or DI Water) on 
Embryonic Mortality, December 2007
This was the preliminary trial of the yolk injection methodology conducted at 
VIMS. Embryos were sacrificed, by design, prior to hatching. A total of 13 eggs were 
used in this trial. The weight losses of the eggs during the incubation were slightly greater 
than optimal, yet not statistically different, see Appendix A: Figure A.I.
The mortality data are presented in Table R. 1. The null hypothesis tested here 
was that yolk injection (DI water or emulsion) would have no effect on embryonic 
mortality. The Chi-Square value was equal to 10.19 with a corresponding P<0.05.
There was a significant treatment effect on survival. It is hypothesized that the yolk- 
injections of DI water caused osmotic shock and embryonic death. The DIH20 treatment 
group was excluded from the analysis of the remaining data, as subsequent BDE-209 
exposures did not involve DI water as a carrier, Using the remaining data, a Chi-Square 
value of 0.99 was calculated with a resulting p-value of 0.32. There was no significant 
difference in the mortality between the non-injected and the emulsion injected embryos in 
this small trial.
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Table R.1: The Mortality Data for Trial 1
Survive Dead Total
Percent
Mortality
Non-inject 4 0 4 0
DIH20-inject 0 4 4 100
Emulsion-
inject 4 1 5
25
Total 8 5 13 38
On Day 19 of incubation, the embryos were sacrificed and necropsies were 
conducted. None of the embryos had begun to pip through the eggshell. The embryos 
were fully feathered. However, the yolk sacs were still external. The summary statistics 
for this trial are shown in Table R.2.
Table R.2: Summary Statistics for Trial 1
Treatment EggW t(g)
Crown to 
Rump 
Length (in)
Body Wt 
w/yolk (g)
Yolk Sac Wt
(g)
Liver Wt
(g)
Brain Wt
(g)
Vehicle-lnject
Mean 58.67(4.14) 3.52(0.21) 44.60(8.12) 16.67(6.01) 0.59(0.14) 0.67(0.12)
Non-lnject
Mean 59.07(3.46) 3.57(0.21) 49.57(2.8) 22.12(1.01) 0.55(0.06) 0.66(0.09)
Mean of all 58.84 (3.55) 3.55(0.20) 47.09(6.22) 19.40(4.99) 0.57(0.10) 0.66(.10)
Standard deviations reported in ().
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The null hypothesis tested was that there were no differences between the various 
measurements in the two treatment groups. One-way ANOVA and follow up Tukey’s 
Test were run on the above measurements. No significant differences were detected 
between the emulsion-injected and the non-injected groups.
R.2: Trial 2: Testing the effect of yolk-injection on embryonic mortality, (February 
2008)
In this trial an automated egg turner was used. A sham injection treatment group 
was substituted for the DI water injection treatment to examine the impact of the physical 
trauma associated with the injection process. The mortality data for Trial 2 are 
summarized in Table R.3. The null hypothesis tested here was that there was no 
difference in mortality between eggs injected with the emulsion, sham injected, or non­
injected (not-drilled) eggs. The Chi-Squared value calculated for this trial was 1.7 with a 
corresponding p value of 0.43. This suggests that there were no significant differences in 
mortality between the three different treatments. However, mortalities for all treatments 
were high, ranging from 25% to 66%.
The moisture loss data for this trial are presented in Appendix A Figure A.2 . The 
moisture weight loss was less than optimal, although again not statistically different.
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Table R.3: Mortality Data for Trial 2
Survive Dead Total
Percent
Mortality
Non-inject 12 3 15 20
Sham-inject 9 6 15 40
Emulsion-
inject 9 6 15
40
Total 30 15 45 33
R.3: Trial 3: Testing the effects of a single BDE-209 dose on embryonic mortality, 
June 2008
In this trial three treatments were examined: an 80 pg/egg BDE-209 dose, vehicle, 
and non-injected control. Mass mortality of the BDE-209 injected group occurred within 
two days of treatment. The mortality data for this trial are presented in Table R.6. The 
Chi-Squared calculated from this table equaled 139.8 (P<0.001). Again the data 
suggested an impact of yolk injection on embryonic mortality. By removing the non­
injected control group from the analysis, we can determine if there is a statistical 
difference between the impact of the emulsion vehicle on embryonic mortality versus the 
impact of the BDE-209. Contingency analysis performed on these data yielded a Chi- 
Square of 103.8 (P<0.001). There was a significant impact on embryonic mortality when 
BDE-209 was injected into the yolk, compared to the vehicle emulsion itself. BDE-209 
was toxic to embryonic chickens at a dose of 80 pg/egg.
This is the first trial that was run at the PWRC. PWRC performs regular egg 
incubation studies and has superior equipment to monitor and control incubator humidity. 
The moisture loss data for this trial are presented in Appendix A Figures A.3 through
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A.5. Figure R.6 tracks the moisture weight loss of the BDE-209 injected eggs. Of the 
three treatment groups, the BDE-209 injected group deviated the most from the ideal 
moisture weight loss function, likely due to the fact that almost all (77 of 79) died 
following the injection. Only two embryos survived through to Day 19. The ideal 
moisture weight loss function was determined to be 16% of the Day 0 weight at hatch, 
day 21. The mean of all eggs within a treatment group on day 0 was multiplied by 0.84 
to determine the ideal average weight at hatch, day 21. The two points were then plotted 
and a line was drawn to give the ideal moisture weight loss function. Therefore, an 
average of 79 egg weights was used to determine the function shown in Figure R.6. Only 
2 eggs were actually tracked through to the completion of the study.
Table R.4: Mortality Data from Trial 3
Survive Dead Total
Percent
Mortality
Non-
inject 38 1 39 3
Vehicle 66 14 80 17
Deca 2 77 79 98
Total 106 92 198 47
R.4: Trial 4: Testing the effect of multiple doses of BDE-209 on embryonic 
mortality, July 2008.
Three BDE-209 doses were injected into chicken yolks. The injection volume 
was 50 pL. The high dose was 40 pg/egg or 800 pg/mL, the middle dose 20 pg/egg or 
400 pg/mL and the low dose 5 pg/egg or 100 pg/mL. The mortality data from this trial
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are presented in Table R.5. The null hypothesis tested was that the various doses of 
BDE-209 injected into the yolks would have no affect on embryonic mortality. The Chi- 
Squared value for this table equaled 34.5 (df = 4) with P<0.001. There was a clear dose 
response relationship, as shown in Fig R.7.
Table R.5: Mortality Data from Trial 4
Survive Dead Total
%
Mortality
Non-
Inject 30 0 30 0
Vehicle 39 4 43 9.3
Low
Dose 42 8 50 16
Mid
Dose 37 11 49 22
High
Dose 24 23 47 49
Total 172 46 219
Figure R.1: Tracking Mortality of 5, 20 or 40 fig/egg doses of BDE-209 in embryonic
chickens versus vehicle control and non-injected treatments
110
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Significantly different from the Vehicle Control at a o f  0.05
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R.4.1 Analysis of Tissue Weights from Trial 4
On Day 20 of Trial 4 the viability of the eggs in all of the treatment groups were 
evaluated using the Vetronic Buddy instrument.. All embryos that were alive on the 
morning of Day 20 were set to be removed from the eggs and sacrificed by decapitation. 
The Middle Dose (n = 41) and the Vehicle (n = 40) treatment groups were necropsied and 
various tissue weights were collected. Mortality occurred on Day 20 between the 
morning measurements and later sacrifices in both of these treatment groups. In the 
Middle Dose treatment group 4 embryos were dead at the time of removal from the egg. 
In the Vehicle treatment group, 5 of the embryos were dead at the time of removal from 
the eggs. Following death in the egg, the embryonic tissues begin to fill with fluid. The 
resulting edema skewed the weight measurements taken from embryos that died before 
removal from the egg shell. Therefore the data from these individuals were excluded 
from the following analysis of the tissue weights.
Table R.6 presents the tissue weight data from Trial 4. Two-sample T-Tests were 
run to determine if BDE-209 had any impact on tissue weights. The null hypotheses were 
that there are no differences between the mean tissue weights from the two treatment 
groups. At a=5%, none of the treatments were significantly different.
Often data for individual tissues are expressed as ratios relative to the total body 
weight instead of as raw values. The calculation to convert the raw value to the tissue 
index is shown below.
Tissuelndex = TissueWeiSht *l00 
Total Body Weight
The transformed tissue data are presented in Table R.7. Two-sample T-Tests 
were run to determine if BDE-209 had any impact on tissue weights. The null
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hypotheses were that there are no differences between the mean tissue indices from the 
two treatment groups. Again, at a= 5% none of the treatments were significant.
Table R.6: Mean (Standard Deviation) Tissue Weights from Trial 4
TREATMENT
Body wt w/ 
yolk (g) Yolk (g)
Liver
(mg)
Brain
(mg)
Muscle
(mg)
Sample
size
VEHICLE 41.0(3 .68) 10.5(2.06)
570
(107)
867
(68.6)
178
(28.4) 35
DECA MID 
DOSE 39.8(3.36) 10.1(1.71)
590
(81.2)
877
(62.0)
187
(26.7) 37
Table R.7: Mean (Standard Deviation) Tissue Indices from Trial 4
TREATMENT Liver Index Brain Index
Heart
Index Sample size
VEHICLE 1.8 7(0.35) 2.84 (0.32) 0.58 (0.10) 35
DECA MID 
DOSE 1.99 (0.24) 2.96 (0.30) 0.63 (0.08) 37
R.5: Dose Verification
The high dose was extracted efficiently with recoveries of 85-98%. The middle 
dose had lower extraction efficiency with recoveries ranging from 51-79%. The low dose 
extractions yielded much lower concentration estimates than expected, i.e. 19, 39 and 
52% recovery. The expected concentration of the diluted low dose extractions was lower 
(983 ng/mL) than the medium and high doses (1600 ng/mL). As expected, BDE209 was 
not detected in the vehicle extractions. These extracts were much more concentrated than 
the others, which required substantial dilution to allow BDE-209 quantitation.
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Table R.8: Dose Verification
Sample
BDE209
(ng/ml)
Expected
BDE209
(ng/ml)
% Rec. 
BDE209
HIGHDOSEREP1 1430 1600 89
HIGHDOSEREP2 1570 1600 98
HIGHDOSEREP3 1370 1600 86
MEAN (SD) 1450(100) 91 (6.4)
MEDDOSEREP1 830 1600 52
MEDDOSEREP2 1120 1600 70
MEDDOSEREP3 1270 1600 79
MEAN (SD) 1070(223) 67 (14)
LOWDOSEREP1A 186 983 18
LOWDOSEREP2A 507 983 52
LOWDOSEREP3A 384 983 39
MEAN (SD) 359(160) 36 (16)
VEHREP1 ND 0 NA
VEHREP2 ND 0 NA
VEHREP3 ND 0 NA
The BDE-209 standard used in the making of the dosing formulations in this 
study was high purity, i.e. >98%. Does not look that high in your below figure However, 
the presence of small amounts of nona-BDEs in the BDE-209, and therefore the dosing 
solutions, can not be ignored; especially as this study aims to quantify any biological 
debromination that may have occurred. Two of the nona-BDEs (-207 and 206) were 
identified and quantified to account for the entire mass of the powder dissolved in each 
dosing formulation. When the nona-BDEs are taken into account for the medium dose 
dilutions the recoveries improve to 70.5%, 85.9%, and 96.7%, respectively. BDE-206 
was more abundant than BDE-207. In the medium dose extractions BDE-206 
represented on average 15% of the total with BDE-207 contributing 5% of the total 
composition.
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Figure R.2: Medium Dose Verification
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Figure R.3: PBDE Congener Profiles for the Middle Dose and Spiking Solution
100%
%  M e d i u m  D o s e
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R.6: Calculating the LD50
The Median Lethal Dose (LD50) was determined here by following the methods 
presented in the Newman text from 1995. Figures R.7 through R.9 present the SAS 
readouts for the Probit, Logit, and Gompertz Analyses. The Gompertz model had the 
lowest Pearson Chi-Square value. Therefore, the data are a better fit to the Weibull 
distribution. Figures R.4 through R.6 revealed that the three models all generated 
equivalent values for the LD50.
The three models (Probit, Logit, and Gompertz) include a term to account for the 
mortality caused by the injection of the vehicle alone. It should be noted here that data 
from trials three and four were used to conduct this analysis. Two different injection 
volumes were used. These data were only pooled together after careful consideration.
The importance of the LD50 metric in toxicology and risk assessment is that it is widely 
used and understood. By pooling the data from two trials, this metric contains more 
information on the toxicity of this compound to embryonic birds. However, the trade off 
is that the information on the toxicity of the emulsion vehicle is less accurate. The reason 
for this is that in trial three 100 pi of vehicle were injected and in trial four only 50 pi of 
the vehicle were injected. Therefore the vehicle mortality rate of 16.8% is likely 
overestimated for the 50 pi injections and is underestimated for the 100 pi.
All three of the models calculated an LD50 of 44 pg/egg for a 16-day in ovo 
exposure. The estimated mortality rate from exposure to the emulsion vehicle ranged 
from 16-18%.
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Figure R.4: SAS Readout for Probit Analysis
Probit Analysis (assuming a normal distribution)
Pearson Chi-Square 
L.R. Chi-Square
G oodness-of-Fit Tests 
Value
2.3325
2 .1 /17
Pr > ChiSq
0.3115
0.3376
A nalysis of Parameter Estim ates
Standard 95% Confidence Chi- 
Param eter DF Estim ate E rror Limits Square Pr > ChiSq
In te rc e p t 1 -11.4285 2.6205 -16.5645 -6.2924 19.02 <.0001
LoglO(CONC) 1 6-9646 1.5074 4.0101 9.9191 21.35 <.0001
C 1 0.1827 .0.0286 0.1268 0.2387
P ro b it P rocedure 
P ro b it  A na ly sis  on CONC
P ro b a b il i ty
0.45
0.50
0.55
CONC
41.96547 
43 74565 
45.60136
95% F id u c ia l  L im its
32.79999 
34.99876 
37.2854 1
48.00176 
49.78320 
51.71317
Pearson Chi- 
Squared
Estimate of 
natural 
mortality rate
LD50 = 43.75 
ug/egg
Figure R.5: SAS Readout for Logit Analysis
Logit Model (Assumes a Logistic distribution)
Statistic
Pearson Chi-Square 
L.R. Chi-Square
Goodness-of-Fit Tests 
Value
2 .1 1 0 0  
1.9738
DF
A nalysis  of Param eter E stim ates 
S tandard  95% Confidence
Pr > ChiSq
0.3482
0.3727
Param eter DF E stim ate  E rro r L im its
Chi-
Square Pr > ChiSq
In te rc e p t  1 -20.4372 4.9116 -30.0638 -10.8106
LoglO(CONC) 1 12.4847 2 .9 0 7 8 6 .7 8 5 5  18.1839
C 1 1 0.1816 0.0284 0.1259 0.2372
P r o b i t  P rd b ed u re
17.31
-f&r43
< .0 0 0 1
<.0001
Probability
0.45
0.50
0.55
P r o b i t  A n a ly s is  on CONC
CONC 95% F id u c i a l  L im its
41.77389 
43.34891 
44.98332
34.15946 
36.15814 
38.17955
47.26338 
49.02738 
50.98271
Pearson Chi- 
Squared 
2.11 < 2.33
The logit model fits 
better than the 
probit model
Estimate of 
natural 
mortality rate
LD50 = 43.34 
ug/egg
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Figure R.6: SAS Readout for Gompertz Analysis
Gompertz Model (Assumes an exponential/Weibull distribution)
Statistic
Pearson Chi-Square 
L.R. Chi-Square
Goodness-of-Fit Tests 
Value
0.5129
0.5007
Pr > ChiSq
0.7738
0.7785
Analysis of Parameter Estimates
Standard
Parameter DF Estimate Error
95% Confidence 
Limits
Chi-
Square Pr > ChiSq
Intercept 1 -10.5079 2.0225 -14.4719 -6.5439 26.99 <.0001
Ln(CONC) 1 2.6783 0.4848 1,7281 3.6285 30.52 <.0001
_C_ 1 0.1682 0.0295 0.1103 0.2261
Probit Procedure
Probit Analysis on CONC
Pearson Chi- 
Squared
0 .5 1 2 9 < 2.11
The Gompertz model 
fits better than the 
logit model
Estimate of 
natural mortality 
rate
Probability
0.45
0.50
0.55
CONC
41.73140 
44.10107 
46.49370
95% Fiducial Limits
31.63374 
34.29392 
37.01070
48.68537
50.95795
53.28432
LD50 = 44.10 
ug/egg
Total egg weight changed throughout the course of incubation (-16%) due to 
moisture weight loss. The mean initial egg weight was 59.7 g. This yields an LD50 
concentration of 740 ng/g egg. If one corrects this value for ideal moisture weight loss of 
16% then the value rises to 880 ng/g egg.
In examining the potential toxic impact of these levels of BDE-209 on real world 
bird populations, different lethal dose metrics may be examined. Again the accuracy of 
these numbers decreases as we move away from the middle (LD50) of the CDF. The 
LD10 calculated by the Gompertz model in this study is 21.8 pg/egg. This equates with 
365 ng/g egg.
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R.7: BDE-209 Egg Distribution and Biotransformation 
R.7.1: Method Development
The solid-phase extraction (SPE) step has been used in the VIMS lab as a viable
step for eliminating co-extracted biogenics from a variety of matrices. However, 
preliminary analysis by GC/MS of some egg extracts suggested that excessive biogenic 
interferences remained in the purified extract if the solvent regime typically used was 
employed. Weaker solvent regimes might elute off less material, so alternative column 
elution options were examined. Initially only 100% hexane was used. BDE-209 was 
eluted, but required a high volume (15 ml) of solvent. During these trials, it became 
apparent that the interaction of bromine with the silica gel column caused the PBDEs to 
elute off the column in an unexpected manner. BDE-209, the fully brominated congener, 
was expected to be the last of the PBDE congeners to elute from the silica gel column. 
However, BDE-209 was actually the first PBDE to elute.
R.7.2: 10% DCM SPE test
A solvent regime of 10% DCM and 90% hexane was next tested. Three replicates
were run. The column was prepped with 5 ml of 100% hexane. The SPE columns were 
spiked with 1000 ng BDE209, 480 ng PCB204, and 480 ng BDE166. The first fraction 
was eluted with 3 ml of hexane and discarded. The second (S2) fraction consisted of 8 
ml of 10% DCM 90% hexane. This was collected, reduced to < 1ml and spiked with 300 
ng DCDE as internal standard before GC/MS analysis. The third (S2_A) fraction 
consisted of an additional 3 ml of 10% DCM. The fourth and fifth fractions (S2_B and 
S2_C, respectively), were also 3 ml of 10% DCM. These were also reduced to <lml and 
spiked with 300 ng of DCDE as an internal standard. In all three replicates BDE-166
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appeared in the S2_A fraction. The appearance of BDE-209 in the S2_C fraction of 
replicate 2 was unexpected and may be due to contamination.
Figure R.7: Data from the SPE 10% DCM Test
1200.00
1000.00
R eplicate and Fraction
□  BDE209 (ng) SPC B 204(ng)____________________ OBDE166 (ng)
R.7.3: PBDE Spike Recovery Study
The results of the egg spiking experiments indicated the recoveries of all the 
compounds except BDE-47 and PCB-204 exceeded 80% (Table R.6). Some BDE-47 
may still have been retained on the SPE after elution. The overall focus of the project 
was on BDE209 and the most likely degradates (nona- and octa- PBDE congeners), so 
some loss of low brominated congeners, e.g. tetrabrominated BDE-47, was deemed 
acceptable, especially in the face of greater elution of chromatographically co-eluting 
biogenic interferences.
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R.7.4: QA/QC
Sodium Sulfate (Blanks) samples were run with each pool of 10 samples. The data 
from these samples are presented in Table R.10. BDE-209 was not detected in any of these 
blank samples.
164rceLimitofQuantitation —------------------- = 290ng / e
(lg)* (0.5625)
Blank 3 shows a very low recovery of BDE-166. The sample was re-run and the 
results were the same. The peak for BDE-166 was definitely present yet the concentration 
was too low to quantify.
Table R.10: Sodium Sulfate Spiked Blank Samples
Sample ID
BDE209
(ng/ml)
BDE166
(ng/ml) % REC
BLANK-2 ND 351 62.4
BLANK-3 ND <290 NA
BLANK-4 ND 505 101.0
BLANK-5 ND 330 66.0
BLANK-6 ND 409 81.8
BLANK-7 ND 485 97.0
BLANK8 ND 632 126.4
BLANK-2
RERUN ND 417 74.1
BLANK-3
RERUN ND <290 NA
BLANK-5
RERUN ND 328 58.3
BLANK-8
RERUN ND 471 83.7
R.7.5: Results from Distribution Study
Tables R.l 1 through R.20 summarize the data from the 80 injected egg samples 
collected in the BDE-209 distribution study. These tables are organized by tissue type and 
treatment group. The samples are named by tissue type (i.e. B = brain, C = carcass, Y = Yolk, 
L = Liver, H = Heart) then treatment (V = Vehicle D = Dosed) and the number of the sample 
pool. Each pool number equates with the same four birds, e.g. sample BD4 contains the
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brains of the birds whose carcasses can be found in sample CD4. This allows for both 
analysis of tissue mean values and individual pool values.
The quality of the data is evaluated by the percent recovery of the surrogate standard 
BDE-166. Any samples where the percent recovery of the surrogate standard was >120% or 
<70% or were rerun on the GC/MS. The data from the reruns are reported in the appropriate 
table.
Note that the third column in each table entitled “Corrected [BDE-209] (ng/g lw)” 
contains the following formula:
CorrectedConcentration[BDE -  209] = (AmountBDE ~ 209) * (0-5625) ^ } g6% Re ^  ^
Upidwt
The constant 0.5625 is the percentage of the ASE sample either not used in lipid 
analysis (10% of the sample is consumed in the gravimetric determination of the sample lipid 
content) or un-injected in the size exclusion process. In the SEC step the total sample volume 
is diluted to 8 ml and the sample is split in two for loading onto the HPLC. The sample 
volume charged to the SEC column actually occurs as two injections; one from each 4 ml 
sample aliquot. Each injection is only 2.5 ml. So a total of 5 ml of the 8 ml total sample 
reaches the column. This is a ratio of 5/8 of the original sample AFTER 10% has been 
removed for lipid analysis, hence the 0.5625 factor.
The calibration curve used to quantify BDE-209 (Figure R.8) ranged from 50 ng/ml 
BDE-209 to 2000 ng/ml BDE-209. This curve was linear with an R-Squared value of 0.9713.
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Figure R.8: BDE-209 Calibration Curve
BD E-209 Calibration Curve y = 1.4482X -0 .0116 
R2 = 0.9713
CT>
CM
0.5 1.5 2 2.5
(Area BDE-209)/(Area DCDE)
3.5
R.7.5.1: Brain Samples
BDE-209 was not detected in any of the brain samples from the vehicle treatment 
group. (Table R. 12) BDE-209 was detected at high levels in only one of the original brain 
samples from the dosed treatment group. (Table R.l 1) This sample (BD8) was rerun (BD8- 
R) and still exhibited high BDE-209 concentrations. BDE-166 recovery was 91%. It is 
unlikely that such high levels would be detected in only one of the original dosed brain 
samples. It is much more likely that this large BDE-209 signal represents cross­
contamination in the laboratory.
After initial analysis the dosed brain samples were reduced in volume and pooled 
together from a total of 7 individual samples (BD8 was not pooled) into two samples. These 
composite samples were then analyzed by GC/MS. The results are presented in Table R.l 1 A.
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Table R .ll: BDE-209 in Brain Samples from Middle Dose and Vehicle Yolk-injected
 _________ ,___________  Eggs_________ _________ _________
Sample
ID
Corrected 
[BDE209] 
(ng/g ww)
Corrected 
[BDE209] 
(ng/g Iw)
BDE166
(ng) % REC % lipid
BD2 ND ND 453 81 28
BD3 ND ND 409 73 30
BD4 ND ND 393 79 27
BD5 ND ND 338 68 30
BD6 ND ND 484 97 26
BD7 ND ND 381 76 28
BD8 540 9400 551 110 35
BD8-R* 380 6600 514 91 35
MEAN 83 30
STDEV 15 3.4
BV2 ND NA 482 86 34
BV3 ND NA 373 66 39
BV3-R* ND NA 271 48 39
BV4 ND NA 541 108 13
BV5 ND NA 401 80 96
BV6 ND NA 592 118 29
BV7 ND NA 583 117 28
BV8 ND NA 518 104 4.8
MEAN 97 35
STDEV 20 25
* The -R  indicates this is a rerun o f  the sample. “B ” indicates Brain Sample, “D” indicates from the middle 
dosed group, “V ” indicates from the vehicle control group. The number in the sample ID refers to the specific
samples pool.
Table R.11A: BDE-209 in Composite Brain Samples from BDE-209 -injected Eggs
BDE209 
ng/g dw BDE166
%Recovery
BDE-166
NEWBRAIN1 56 1920 114
NEWBRAIN2 ND 2150 127
*NEWBRAIN1 contains samples BD1, BD2, BD3, and BD4 
*NEW BRAfN2 contains samples BD5, BD6, and BD7. 
BD8 was not pooled due to the high levels o f  BDE-209 present.
R.7.5.2: Carcass Samples
Each carcass sample extracted had a dry weight of 1.5 grams. The average lipid
weight of the carcass samples was 0.405 g. The lowest point on the GC/MS calibration curve 
was 50 ng/ml. The calculations to determine the limit of quantitation are shown below.
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50 ti pLimitofQuantitation = -------------     = 219«e / glw
(0.405#)* (0.5625)
BDE-209 was not detected in any of the vehicle exposed carcass samples, see Table 
R.13. BDE-209 was detected in all dosed carcass samples, see Table R.14. The mean 
concentration of BDE-209 in the dosed samples was 574 ng/g lw.
Table R.12: BDE-209 in Carcasses from Middle Dose and Vehicle-injected eggs
Corrected 
[BDE209] 
(ng/g ww)
Corrected 
[BDE209] 
(ng/g lw) BDE166 % REC % lipid
CD2 27.0 509.8 429 76.3 27.1
CD3 26.4 529.5 459 81.6 25.4
CD4 18.9 345.8 470 83.6 27.9
CD5 18.7 355.2 416 74.0 26.9
CD6 26.8 534.2 585 104.0 25.6
CD7 25.8 510.6 416 74.0 25.8
CD8 65.7 1235.4 533 94.8 27.1
MEAN 29.9 574.4 MEAN 84.0 26.6
STDEV 16.2 302.5 STDEV 10.6 0.9
CV2 ND ND 511 90.8 27.5
CV3 ND ND 418 74.3 27.3
CV4 ND ND 476 95.2 26.5
CV5 ND ND 385 77.0 27.5
CV6 ND ND 589 117.8 26.9
CV7 ND ND 443 88.6 23.6
CV8 ND ND 563 112.6 32.6
MEAN 93.8 27.4
STDEV 16.5 2.7
“C” indicates Carcass Sample, “D” indicates from the middle dosed group, “V” indicates from the vehicle 
control group. The number in the sample ID refers to the specific samples pool.
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R.7.5.3: Liver Samples
The amount of sample available from the pooled livers averaged 0.78 g. The average 
lipid weight of the liver samples was 0.39 g. The calculations to determine the limit of 
quantitation for these samples are shown below.
50ngLimitofQuantitation  ------------------------= 221 ng I glw
(0.39^) *(0.5625)
BDE-209 was detected in only one of the vehicle-exposed liver samples, see Table 
R.16. This sample, LV7, was identified as an outlier and was rerun. LV2 was dropped 
during processing and lost. BDE-209 was detected in all dosed liver samples, see Table R.17. 
Three of these samples have recoveries below 70% for BDE-166 and were rerun
The mean concentration of BDE-209 in the dosed liver samples was 3640 ng/g lipid weight.
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Table R.13: BDE-209 in Liver from Middle Dose and Vehicle-injected Eggs
Sample
ID
Corrected 
[BDE209] 
(ng/g ww)
Corrected 
[BDE209] 
(ng/g lw) BDE166 % REC % lipid
LD2 749.3 5307.8 393 69.9 38.8
LD2-R* 225.8 1599.7 283 50.3 38.8
LD3 743.8 4690.6 372 66.1 43.6
LD3-R* 209.1 1318.8 648 115.2 43.6
LD4 749.5 4810.5 449 89.8 42.8
LD5 971.7 2222.2 326 65.2 120.1
LD5-R* 313.6 717.2 352 70.4 120.1
LD6 893.3 5745.0 533 106.6 42.7
LD7 679.4 5294.0 493 98.6 35.3
LD8 691.6 4658.9 497 99.4 40.8
MEAN 622.7 3636.5 MEAN 83.2 56.6
STDEV 273.6 1931.1 STDEV 21.5 33.6
LV3 ND ND 664 118.0 29.0
LV4 ND ND 409 81.8 35.6
LV5 ND ND 320 64.0 47.4
LV5-R* ND ND 269 53.8 47.4
LV6 ND ND 566 113.2 40.8
LV7 128.000633 927.9895732 453 90.6 37.9
LV8 ND ND 505 101.0 36.4
MEAN 88.9 39.2
STDEV 24.1 6.6
* The -R  indicates this is a rerun o f the sample. “L” indicates Liver Sample, “D” indicates from the middle 
dosed group, “V" indicates from the vehicle control group. The number in the sample ID refers to the specific
samples pool.
The nona BDEs were detected in all of the dosed liver samples. The data are 
presented in Table R.14.
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Table R.14: Nona-BDEs in Dosed Liver samples
SAMPLE
ID
Corrected 
[BDE206] 
(ng/g lw)
Corrected 
[BDE207] 
(ng/g lw)
Corrected 
[BDE208] 
(ng/g lw)
LD1 104.1 129.9 22.0
LD2 175.2 245.2 108.8
LD3 225.0 219.4 64.9
LD4 376.2 443.2 152.0
LD5 135.2 114.7 37.8
LD6 529.1 574.7 125.6
LD7 613.4 674.5 269.3
LD8 198.1 303.1 86.6
Mean 294.6 338.1 108.4
STDEV 190.3 206.1 78.3
“L” indicates Liver Sample, “D” indicates from the middle dosed group, “V” indicates from the vehicle control 
group. The number in the sample ID refers to the specific samples pool.
R.7.5.4: Heart Muscle Samples
The amount of sample available from the pooled heart muscles averaged only 0.1 g.
The average lipid weight of the heart muscle samples was 0.019g. The calculations to 
determine the limit of quantitation for these samples are shown below.
50 ngLimitofQuantitation = --------------------------= 4700ng/ glw
(0.019g)* (0.5625)
BDE-209 was not detected in any of the vehicle exposed heart samples, see Table 
R. 18. BDE-209 was also not detected in any of the original dosed heart samples, see Table 
R.19. The final pre-GC injection volume of these samples was 1 ml. The dosed heart samples 
were blown down and pooled together from 8 original samples into 2 new samples and rerun. 
The calculations for the new limit of quantitation are shown below.
50 m*
LimitofQuantitation = ----------------------------- -1700ng!glw
(0.019g * 4) * (0.5625)
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Table R.15: BDE-209 in Heart from Middle Dose and Vehicle-in jected Eggs
Sample
ID
Corrected 
[BDE209] 
(ng/g ww)
Corrected 
[BDE209] 
(ng/g lw) BDE166 % REC % lipid
MD2 ND ND 429 76.3 20.0
MD3 ND ND 393 69.9 14.0
MD3-R* ND ND 507 90.1 14.0
MD4 ND ND 468 93.6 22.0
MD5 ND ND 277 55.4 36.0
MD5-R* ND ND 398 70.8 36.0
MD6 ND ND 574 114.8 18.0
MD7 ND ND 453 90.6 18.0
MD8 ND ND 715 143.0 18.0
MD8-R* ND ND 663 117.9 18.0
MEAN 92.2 21.4
STDEV 26.5 7.6
MV2 ND ND 430 76.4 4.0
MV3 ND ND 812 144.4 16.0
MV4 ND ND 491 98.2 13.0
MV5 ND ND 439 87.8 31.0
MV6 ND ND 522 104.4 10.0
MV7 ND ND 399 79.8 11.0
MV8 ND ND 505 101.0 19.0
MEAN 98.9 14.9
STDEV 22.7 8.6
* The -R  indicates this is a rerun o f the sample. “M” indicates Heart Muscle Sample, “D” indicates from the 
middle dosed group, “V” indicates from the vehicle control group. The number in the sample ID refers to the
specific samples pool.
Table R.15A: BDE-209 in Composite Heart Samples from BDE-209 injected Eggs
BDE209 
ng/g dw BDE166
%Recovery
BDE-166
NEWHEART1 245 1950 116
NEWHEART2 184 1980 117.
*NEWHEART1 contains samples MD1, MD2, MD3, and MD4 
*NEWHEART2 contains samples MD5, MD6, MD7,and MD8.
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R.7.5.5: Yolk Samples
Each yolk sample had a dry weight of 1.0 g. The average lipid weight of the yolk 
samples was 0.4 lg. The calculations to determine the limit of quantitation for these samples 
are shown below.
Lower lim itofQuantitation = ------- 200ng _ g^y /
(0.41#) *(0.5625)
The highest point on the extended GC/MS calibration curve was 2000 ng/ml. The 
calculations to determine the upper limit of quantitation for the curve are shown below.
UpperLimitofQuantitation = ------ -000/7#------- _ g^yQ / gjw
(0.41#) * (0.5625)
BDE-209 was not detected in any of the vehicle-injected yolk samples, see Table 
R.19. The dosed yolk samples were all run in triplicate, as there was plenty of material 
available for analysis. BDE-209 was detected in all dosed yolk samples. The mean 
concentration of BDE-209 in the dosed samples was 6000 ng/g lw. Many of the detected 
values were above the upper limit of quantitation identified above.
The yolk samples were diluted 5-fold to bring the BDE-209 concentrations within the 
range of the calibration curve. These concentrations were found to be reasonable and well 
within the expected range given the total dose administered to the embryos. Therefore, 
further work with 13C-labeled BDE-209 was not required.
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Table R.16: BDE-209 in Yolk from Vehicle-injected Eggs
Sample ID
Corrected 
[BDE209] 
(ng/g ww)
Corrected 
[BDE209] 
(ng/g lw)
BDE166
(ng/ml) % REC % lipid
YV2 ND ND 437 77.7 32.2
YV3 ND ND 371 66.0 38.7
YV4 ND ND 496 99.2 45.8
YV5 ND ND 516 103.2 44.5
YV6 ND ND 429 85.8 42.8
YV7 ND ND 536 107.2 43.6
YV8 ND ND 507 101.4 48.9
MEAN 91.5 42.4
STDEV 15.4 5.4
‘Y” indicates Yolk Sample, “D” indicates from the middle dosed group, “V” indicates from the vehicle control 
group. The number in the sample ID refers to the specific samples pool.
Table R.17 : BDE-209 in Diluted Yolk Samples from BDE-209-injected Eggs
Sample ID
BDE-209 (ng/g 
dw)
BDE-209 (ng/g 
lw)
% Recovery BDE- 
166
YD1*A5-1 2213 5533 49.07
YD2*A5-1 3520 8800 58.40
YD3*A5-1 3120 7800 61.78
YD4*A5-1 3947 9867 68.44
YD5*A5-1 3716 9289 45.07
YD6*A5-1 4098 10244 42.40
YD7*A5-1 4240 10600 69.51
YD8*A5-1 3858 9644 65.42
Mean 3589 8972 58
SD 656 1640 10.7
*A5-1 Refers to analytical replicate A diluted by a a factor of 5. “Y” indicates Yolk Sample, “D” indicates 
from the middle dosed group, “V” indicates from the vehicle control group. The number in the sample ID refers
to the specific samples pool.
Nona BDEs were detected in all of the dosed yolk samples. Figure R.9 presents the 
mean values for the three nona-BDEs in the dosed yolk samples.
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Figure R.9: Mean Nona-BDEs in Dosed Yolk Samples
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Two unknown heavily brominated compounds were also detected in YD7 and YD3. 
The chromatograms and spectra for these samples are shown below in Figures R.10 through 
R.22.
YD1 YD2 YD3 YD4 YD5
Sample ID
YD6
BDE-206 □  BDE-207 □ BDE-208
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Figure R.10: Chromatogram of Sample YD7
File: YD7 Date Run: 10-11-2009 (Time Run: 21:45:21)
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The spectra were compared to the spectra from La Guardia’s ECNI BDE Spectra
Library5. The two compounds with retention time 20.52 min. and 22.82 were not identified as
PBDE congeners. They may be potential breakdown products of BDE-209 or contaminants
in the analytical process. From the MS spectra, these two compounds are clearly brominated,
due to the presence of the 79 and 81 m/z and with ion clusters at about 80 m/z intervals
indicative of bromine losses.
The spectrum for Unknown Compound A is shown in Figure R.20. The 722 ion is
indicative of a compound containing seven bromines (12 Carbons, 1 Oxygen, and 7
5 http://www.viins.edu/people/laguardia mi/pubs/LaGuardia Spectra%20Librarv%20- 
%20ECNI%20PBDEs.pdf).
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bromines). This is most likely a polybrominated dibenzofuran (PBDF) with eight bromines. 
The molecular ion was 800 with M-Br at 720 m/z. Figure R.21 shows the basic structure.
Figure R.11: Mass Spectrum of unknown Compound A with Retention Time of
20.52 min.
File: YD7
Sample: YD7 RERUN 
Instrument: JEOL GCmate 
Inlet: GC
11/9/2009
Date Run: 10-11-2009 (Time Run: 21:45:21) 
Ionization mode: CI-
Scan: 779 (764) R.T.: 20.52
Base: m/z 722; 5.4%FS TIC: 419386 (Max Inten : 56848)
100 ,
UNKNOWN A RT=20.52 min
Page 1
#Ions: 251
Figure R.12: Dibenzofuran Molecular Structure
9 1
dibenzofuran
The detection of this brominated furan raises questions. Of paramount importance is 
the origin of this compound. The dose verification samples were re-checked for this 
compound and other fiirans. None were found. The distribution samples were rechecked for 
this and other furans and some samples were found to contain this compound. This 
compound was only detected in the dosed yolk samples and in none of the other matrices 
from the distribution study. More specifically, only three of the dosed yolk samples showed 
the presence of this compound (YD3, YD7, and YD8). However, this PBDF was only 
detected in all three replicates of YD7. Only one replicate for the samples YD3 and YD8 
showed the presence of this compound.
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Figure R.13: Spectrum for Unknown Compound B with Retention Time of 22.82
11/9/2009 Page 1
File: YD7 Date Run: 10-11-2009 (Time Run: 21:45:21)
Sample: YD7 RERUN 
Instrument: JEOL GCmate
Inlet: GC Ionization mode: CI-
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The replicates for sample YD7 showed similar patterns.
The molecular ion is 842, the other clusters are 757, 673 and 599.
It has been suggested that this is a diphenyl ether with not chlorine and bromine substitutions 
that is an impurity in Deca-BDE. There are no data showing that this compound was present 
in ANY of the dosing emulsions. Ion 488 was plotted for the extractions of all the dosing 
formulations to confirm whether or not this was an impurity found in the dose itself. None of 
the medium dose replicates had a peak for ion 488 at the 22.82 retention time. The original
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BDE-spiking solution used to make the dosing emulsions also does not show the presence of 
this compound. None of the Low Dose, High Dose, or Vehicle samples show this compound 
either. The yolk vehicle samples also show no sign of this compound. Again the 488 ion was 
plotted up for each sample.
This compound was found in all three replicates of every one of eight dosed yolk 
samples. The 444 ion was plotted up and all 24 samples had a peak at 22.82 minutes with the 
spectra shown in Figure R.13. The liver samples showed an identical pattern. All eight of the 
dosed liver samples had a peak at 22.82 with a spectra matching Figure HH. None of the liver 
samples in the vehicle treatment showed the presence of this compound.
Examination of the standards used to make the calibration curve revealed the presence 
of this doubly halogenated compound. Therefore, the determination was made that the 
presence of this compound represents analytical cross contamination. Where this compound 
was detected the levels were extremely low; typically below the 1:10 signal to noise ratio 
required for quantitation.
R.7.5.6: Mass Balance Calculations
All the samples collected for the tissue distribution evaluation were derived from the 
Middle Dose treatment group. This treatment group was selected for analysis due to the 
survival rate throughout the experiment. Each egg was injected with 20 pg of BDE-209, so 
each embryo theoretically contained 20,000 ng of BDE-209. During collection the embryos 
were pooled into groups of four. Each pooled sample contains the select tissue from four 
individuals. Therefore, the dose must be summed over four embryos; 80 pg of BDE-209 is to 
be accounted for in the five tissue compartments of the embryo. This analysis first examines
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the data from the entire distribution experiment using the mean concentration values from 
each of the tissue compartments. Follow-up analysis is done examining the individual sample 
pools and can be found in Appendix C.
Figure R.14: Distribution of BDE-209 in Yolk-Injected Chicken Embryos Using Mean
Tissue Concentrations
HEART MUSCLE- 
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13% CARCASS-209
4%
LIVER-Nona-BDEs
0.3%
YOLK-209
81%
The mean total carcass dry weight was 25.8 g. The mean concentration of BDE-209 
detected in the dosed carcass tissue samples was 130 ng/g dw. This gives an average total 
amount of BDE-209 in the carcass tissues of 3400 ng, or 4.25 % of the total dose.
The mean total liver dry weight was 0.92 g. All the liver tissue was utilized during 
sample processing. The mean concentration of BDE-209 detected in the dosed liver samples 
was 1600 ng/g dw. This gives an average total amount of BDE-209 sequestered in the liver of 
1470 ng, or about 2% of the total dose.
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The mean total yolk dry weight was 19.33 g. The mean concentration of BDE-209 
detected in the dose yolk samples was 3600 ng/g dw, yielding an average total amount of 
BDE-209 in the yolk compartment of 69,000 ng. This represents 87% of the total 80,000 ng 
delivered to each sample pool.
BDE-209 was not detected in any of the individual sample pools for the heart and 
brain tissues. The individual sample pools were combined and further concentrated. The 
pools of these small tissues exhibited nondetectable to low concentrations. The mean total 
dry weight of the hearts was 0.16 g. The mean concentration (of the reduced sample size n = 
2) was 214 ng/g dw. This equates to less than 1% of the total dose for the sample pool.
The mean total dry weight of the brain tissues was 0.54 g. BDE-209 was only 
detected in one (65 ng/g dw) of the two concentrated samples. However, this value is used 
due to the fact that the other sample only contained three rather than four of the pooled 
samples. This equates to less than 1% of the total dose.
Consideration of the nona-BDEs (BDE-207, 207 and 208) must also be taken into 
account. The mean total concentration of all three nona-BDEs in the yolk and liver tissues 
were quantified. In the dosed yolk samples, the mean total nona-BDE concentration was 580 
ng/g dw. As the total mean yolk dry weight was 19.33 g, this represents a total nona-BDE 
contribution of 11,200 ng or 14% of the total administered dose. In the dosed liver samples, 
the total mean nona-BDE concentration was 260 ng/g dw. Again, the mean total liver weight 
was 0.92 g, yielding a total of 240 ng, or less than 1% of the total dose.
As the mean nona-BDE concentrations were elevated due to the presence of elevated 
levels in sample pool 7, a pool by pool mass balance analysis is indicated.
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A one-way ANOVA and follow-up Tukey’s test was run to determine if the congener 
composition of the original dose formulation, the yolk and liver compartments were 
statistically equivalent. At a= 0.05, the only statistically significant difference was a higher 
BDE-206 percentage in the dose than the liver or yolks of the bird.
Figure R.15: PBDE Congener Profile for the Dosed Yolk, Dosed Liver, and 
Emulsion Dose
Emulsion Dose
Statistically significant at a  = 0.05.
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DISCUSSION
D.l: Toxicity of BDE-209
Data on toxicity of Deca-BDE to avian species are scarce. The analysis conducted 
here used the nominal concentrations of BDE-209 from trials three and four of this study.
The requirements for this type of survival analysis were met; at least one treatment group 
resulted in a partial kill of the exposed population and there was a clear dose-response 
relationship. In this case, comparison of the Pearson Chi-Square values revealed that the 
Gompertz distribution was the best model, with a calculated LD50 value of 44pg/egg (740 
ng/g ww). Selection of the most appropriate, and therefore accurate model, allows for a 
more accurate elucidation of the LD5 and LD10 values.
The Median Lethal Dose (LD50) is a basic metric used in risk assessment and 
toxicology. It identifies the dose of a given chemical at which half of the exposed study 
population dies. As such, it is useful for comparing the relative toxicities of chemicals. The 
chemical 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is one of the most toxic compounds in 
existence. As such, it is often used as the metric against which other toxins are measured 
against. In terms of Toxic Equivalency Factors (TEF) TCDD has the highest possible score 
of 1. The LD50 value reported for yolk injection of TCDD to chicken embryos is 122 pg/g 
egg (Henshel et al., 1997). This value is about 6000-times smaller than the LD50 value 
calculated in this study. Therefore, BDE-209 is about 6000-times less toxic to developing
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chicken embryos than TCDD. This gives BDE-209 a relative potency of 0.000165 when 
compared to TCDD.
In birds, there are limited data available on the toxicity of PBDEs. Air-cell injection 
of the Penta-BDE mixtures resulted in decreased pipping and hatching success in American 
kestrels but not in chickens or mallards (Mckeman et al., 2009). Based on this dose and 
absorption rate of the dose from the aircell into the embryo, a Lowest Observed Effect Level 
(LOEL) of 1800 ng/g ww was determined. This is higher than the LD50 calculated in this 
study by a factor of 2.43.
In rats, a No Observed Effect Level (NOEL) for Deca-BDE of 8 mg/kg body weight 
per day in a 30 day dosing trial was determined by Norris et al. (1975). This was a traditional 
feeding study where Deca-BDE was added to food using a solvent carrier. The NOEL is a 
more sensitive endpoint than the LD50. It is the lowest treatment dose that elicited no 
statistically significant effect in a study where a dose-response effect was measured. For this 
study the NOEL ranged from 84 to 94 ng/g ww. The reported NOEL values from oral 
toxicity studies in mammals ranged from 100 mg/kg (Zhou et al. 2001) to 23,000 mg/kg (EPA 
2008), with the majority of these studies not determining a LOEL (lowest observable effect 
level). These NOELs are much higher than the LD50 determined in the present study. The 
lack of studies reporting LD50 value for BDE-209 in mammals indicates that the compound is 
not very toxic to mammals in an acute exposure scenario. This is supported by the data 
showing the metabolic breakdown and excretion of BDE-209 in mammals. In birds, this 
mechanism results in the excretion of both the parent compound (BDE-209) and possible 
metabolic products into the egg. This results in a developmental exposure scenario.
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A thorough toxicological review of BDE-209 was released by the US EPA in 2008 
(EPA/635/R-07/008F). Minimal attention in this document was paid to acute lethal effects 
from BDE-209 exposure. In fact, the document fails to report any LD50 values for 
comparison. This is largely due to the fact that BDE-209 is believed to be relatively non­
toxic. PBDEs emerged in the market place at a time when more toxic compounds (i.e. PCBs) 
were being removed due to toxic concerns. In the four decades of PBDE use, data have 
emerged that indicate that these compounds are not benign. Government restrictions are now 
in place limiting the use of PBDEs in a manner reminiscent of the treatment of PCBs. While, 
PBDEs are generally less toxic than their predecessors, the PCBs, they still behave as 
endocrine disrupting compounds (EDCs) in the environment. Therefore, it becomes crucial to 
examine the sublethal toxic effects of PBDEs and BDE-209.
Sublethal effects have been well documented for BDE-209 in mammals. The 2008 
EPA Document (EPA/635/R-07/008F) presents a thorough review of these studies. 
Reproductive and developmental toxicity values are much lower than the subchronic toxicity 
values discussed above for mammals. Neurobehavioral effects relating to chlolinergic system 
have been reported (Viberg et al. 2007). The LOEL values for these types of effects range 
from 6.7 mg/kg (Viberg et al.2007) to 20.1 mg/kg (Viberg et al. 2003) for the single dose 
studies. The LOELs from the multi-dose studies range from 6.1 mg/kg/day (Rice et al. 2007) 
to 500 mg/kg/day (Tseng et al. 2007). The LOEL for the present study was the middle dose 
of 20 (Lig/egg, which equates to 335 ng/g ww to 376 ng/g ww. These LOELs are an order of 
magnitude lower than the lowest values reported in mammals.
In a feeding study of American kestrels exposed to DE-71 and a- 
hexabromocyclododecane (HBCD) (Femie et al., 2009) egg shell thickness declined with
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increasing concentrations of PBDEs and HBCD. This effect was not correlated with levels of 
BDE-183 and -209. The potential for metabolic breakdown of these larger congeners to the 
more potent BDEs exists in the adult bird. Femie et al. go on to postulate that PBDE and 
HBCD related egg shell thinning is already having an observable effect on brood size in 
Europe and the decline of the North American kestrel population.
Evaluating this toxicity value within the context of BDE-209 levels detected in bird 
eggs is important. The LD50 values from this study equated to concentrations ranging from 
740 to 803 ng/g ww . Figure D.l explores published BDE-209 levels in avian eggs. The 
levels of BDE-209 in avian eggs from around the world are all an order of magnitude less 
than the LD50 of 7000 ng/g lw calculated for this study. Conversion of the NOEL and LOEL 
to a lipid weight basis result in a range of 837-1340 ng/g lw (NOEL) and 538-3350 ng/g lw.
In examining the potential toxic impact of these BDE-209 levels on real world bird 
populations, different lethal dose metrics may be examined. Again the accuracy of these 
numbers decreases as we move away from the middle (LD50) of the CDF. The LD10 
calculated by the Gompertz model in this study was 21.8 pg/egg, the LD5 was 16.7 pg/egg. 
These values correspond to a range of 3000 to 3500 ng/g lw for the LD10 value and 2650 to 
2800 ng/g lw for the LD5 metric.
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Figure D.l: Levels of BDE-209 in wild bird eggs from various locations around the
world
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The LD10 and LD5 values are still an order of magnitude higher than the BDE-209 
levels detected in wild bird eggs. (See Figure D.l) The conclusion of this analysis is that 
BDE-209 levels in wild bird populations are lower than the threshold values for acute toxicity. 
It must be noted, that as the true mechanism of BDE-209 toxicity is not known in avian 
embryos, the potential for chronic effects still exists. Note that uncertainty factors applied are 
typically a factor of 10. Also that, in the present study, exposure was terminated before 
assimilation of the yolk sac and that the 80% of the BDE-209 remained in the yolk.
Additional work is indicated to examine the distribution of this BDE-209 between waste and 
yet unutilized energy reserves and the potential impact of assimilation of the BDE-209 
associated with the latter.
In an effort to explore sublethal endpoints in the present study, the embryos from the 
middle dose (20 pg/egg) and the Vehicle treatment groups were necropsied and the weights of
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five tissues determined. Exposure to BDE-209 through yolk injection caused no significant 
change in brain weights, yolk weights, liver weights, heart weights, or total body weight. The 
tissue weight data were then transformed into a biological index value that expresses an organ 
weight as a percentage of total body weight. Again a one-way ANOVA with follow up 
Tukey’s test was run. No statistically significant differences were detected between the tissue 
weight values or indices of the dosed and vehicle control injected embryos. However, the 
presence of edema and death in many of the embryos at the time of sampling precluded the 
use of tissue weight data in the analysis.
D.2: Dose Verification
Qualitative and quantitative dose validation is an important step in toxicological 
studies. The results of the dose verification indicated that the nominal doses were accurate 
enough to be used in the survival analysis and calculation of the LD50. The confirmation of 
the High Dose was the most consistent. The mean recovery was 91% with a standard 
deviation of 6%. The concentration of the High Dose emulsion was 800 pg BDE-209 per ml 
of emulsion. This High Dose emulsion was used in both trials three and four. In trial 3, 100 
pi or 80 pg BDE-209 per egg of the High Dose emulsion was administered to the BDE-209 
treatment group. In trial four, only 50 pi or 40 pg BDE-209 per egg of the High Dose 
emulsion was administered to the High Dose treatment group. In the survival analysis, the 
data from 5 treatments were used to create the CDF; the 80, 40, 20, 5 and the 0 pg BDE-209 
per egg (vehicle treatment). Therefore, the confirmation of the High Dose at 91% recovery 
supports the accuracy of the dosages administered to both the 80 pg BDE-209 per egg 
treatment group and the 40 pg BDE-209 per egg treatment group.
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Impurities within the technical BDE-209 used to make the emulsions must also be 
considered. In Figure R.l the contributions of the BDE-206 and -207 are illustrated 
(determined from the Medium Dose Emulsion). When the concentrations of these two nona- 
BDE congeners are summed with the BDE-209 concentrations, the recoveries for the Medium 
Dose Emulsion are improved. The mean recovery for the Medium Dose Emulsion, 
accounting for the nona-BDEs, was 84.7%.
The possibility of non-PBDE impurities must also be addressed. BDE-209 is known 
to undergo photolytic debromination and furan formation (Hagberg et al. 2006, Kajiwara et al. 
2008). Furans are highly toxic compounds. No fiirans were detected in the extracts of the 
dosing solution. Careful screening of the dose extracts was made for the Octa-PBDF that 
was identified in some of the dosed yolk samples. Again no furans were detected in any of 
the dosing solutions. This is likely due to the fact that BDE-209 solutions and emulsions 
were ALWAYS stored in amber glassware to prevent photolytic degradation that would 
confound the results of this study.
Even with the nona-BDEs taken into account, the recoveries for the Low Dose 
Emulsion were below 70%. While, this is less than ideal, it is not enough reason to abandon 
the nominal concentrations for the survival analysis. The analysis of the Emulsion Vehicle 
itself revealed no contamination of BDE-209. Therefore, accurate (80% or greater) 
confirmation of four of five doses administered in this study validate the use of nominal 
concentrations in the survival analysis.
The formulation of the emulsion vehicle required a highly concentrated BDE-209 
spiking standard. BDE-209 is not very soluble in most solvents. Analytical standards for 
BDE-209 are not available for over 50 pg/ml. A concentration of 4 mg/ml BDE-209 was
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desired to spike the emulsion formula. This standard was made by purchasing neat BDE-209 
(Wellington Labs, Guelph, Ontario, Canada). The neat BDE-209 was dissolved in a solvent 
mixture of diethyl ether and toluene (1:1 v/v). To accomplish this, a probe sonicator was used 
for 30 minutes. The spiking solution showed 87% of the total PBDEs was BDE-209. The 
Middle Dose extraction has only 76% of the total PBDEs as BDE-209 (See Figure D.2).
There are two possibilities that need to be addressed. First, did debromination of BDE-209 
occur during the sonication and dissolution step? Second, did debromination of BDE-209 
occur during the extraction step of the middle dose analysis?
Figure D.2: PBDE Percent Composition of the BDE-209 Spiking Solution and Middle 
Dose Extraction
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The first question poses an interesting issue. We know that BDE-209 is photolytically 
labile; particularly so, when dissolved in solvent. The sonication/dissolution step was done in 
amber glassware. This reduces the likelihood of the photolysis pathway. The only other
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mechanism would have to involve molecular excitement from the sonicator. While not 
impossible, this is thought to be unlikely.
The second question poses the possibility that debromination occurred during the dose 
extraction process. This is more likely. The emulsified dose was extracted in a separatory 
funnel after dilution. The funnel was not made of amber glass. Therefore, attempts were 
made to shield the contents from light. During the shaking and settling steps, the funnel was 
wrapped in aluminum foil. Unfortunately, the foil had to removed for the collection steps, in 
order to visualize the layers. This may have provided an opportunity for photolysis.
D.3: BDE-209 Egg Distribution and Biotransformation 
D.3.1: Methodology
Chemical analysis of BDE-209 in biological tissues can be difficult due to its high 
molecular weight, high boiling point and potential to thermally degrade in the GC when 
subjected to high temperature. In a GC/MS, coincident biogenic compounds can distort 
chromatography and interfere with signal generation. These issues were observed in the 
course of analyses of some yolk samples in this study. The yolk of a developing chicken 
embryo acts as both a nutritional supply and waste collection compartment, containing lipids 
for consumption and metabolic byproducts, respectively. The analytical procedure was 
designed to remove water (freeze drier), extract lipophilic constituents (ASE) and remove 
extraneous materials from the analytes (SEC and silica SPE steps). Certain tissues, especially 
yolk, liver, and carcasses, contained greater amounts of extractable lipids. In effect, the high 
lipid content of both the yolk and carcass samples limited the amount of sample that could be 
analyzed at once, i.e. 1 and 1.5 g dry weight, respectively.
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The presence of co-extracted biogenic compounds in the samples appeared to interfere 
with the BDE-209 signals in multiple spike recovery tests. Using the original extract 
purification method (LaGuardia et al. 2006a) apparent 2- fold increases in BDE209 was 
observed, for the yolk and carcass samples, respectively, data not shown. In addition, 
biogenic materials co-extracted from these matrices also accumulated on the GC column and 
impacted separation performance. For these reasons, further clean up of the sample extracts 
was required.
Alternate cleanup methods focusing on the final SPE step were investigated. The 
approach was to employ a weaker elution solvent regime to minimize carry-over of co­
extracted biogenics. During the course of this work an interesting finding was made. BDE- 
209 was observed to be the first of the PBDE congeners to elute off the silica gel columns 
used. The initial expectation was that the less brominated congeners would elute earlier and 
BDE-209 would be the last of the PBDEs removed from the column. The opposite trend was 
observed. Grimvall and Ostman (1994) also observed this phenomenon. Bromine atoms are 
larger than chlorine atoms. Bromines are halogens like chlorines, however their placement in 
the periodic table makes them less electronegative than chlorines.
D.3.2: Tissue Distribution of BDE-209
Once an appropriate method of sample clean up was identified, the analysis of the 
samples en mass could begin. The results indicated that BDE-209 was mobilized from the 
yolk, into the heart, brain, liver, and remaining carcass of the developing chicken embryo. 
These findings are consistent with those from Van Den Steen et al. (2008). What remains 
unclear from the tissue distribution data is the true absorption rate of the compound into the
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embryo. The fact that 80% of the total administered dose was found in the yolk clouds the 
issue. It is clear that some of the BDE-209 injected into the yolk was mobilized through the 
embryonic vascular system. It is not clear how much of the dose traveled through the 
embryo. The chicken yolk-sac acts as both a food source and a waste receptacle throughout 
incubation. Therefore, there is no way to confirm if the BDE-209 detected in the yolk-sac 
traveled through the developing embryo and was excreted back into the yolk-sac as waste, or 
if it is simply the unabsorbed remaining dose.
In mammals, neurological toxicity at low BDE-209 concentrations has been reported. 
Viberg et al have published multiple studies showing that neonatal exposure to BDE-209 may 
impact spontaneous behavior and habitutation. Viberg et al (2003) revealed that BDE-209 
can pass the blood brain barrier in neonatal mice. Viberg et al (2007) also showed that rats 
exposed to BDE-209 during the neonatal brain growth spurt show altered responses to 
nicotine in adulthood. Viberg et al (2008, 2009) later examined the impact of neonatal BDE- 
209 exposure to neural protein concentrations in rats. The findings of these studies indicate 
that in mammals BDE-209 enters the brain and alters protein concentrations in ways that can 
cause permanent neurological changes if the exposure occurs during the brain growth spurt 
(BGS).
A major objective of this study was to determine the tissue distribution of BDE-209 
within the avian embryo. Previous work has indicated that BDE209 in rats does not distribute 
strictly according to the concentration of lipid with tissues in rats (Huwe et al 2008). They 
reported preferential accumulation of BDE209 in liver and muscle. BDE-209 was detected in 
one of the composite pooled brain samples. This indicates that BDE-209 does pass the blood- 
brain barrier in the chicken embryo. Therefore, the potential for neurological effects similar
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to those reported in mammals (Viberg et al., 2008) exists in birds. It is also noteworthy, that 
while BDE-209 was detected in very low concentrations (<BQL) in the brains of the dosed 
birds. The BDE-209 detected in the brains of the dosed embryos accounts for only 0.04% of 
the total administered dose. The brain samples were all less than 1 gram. This led to a rather 
high quantitation limit of 2000 ng/g lw.
BDE-209 was also detected (Below the Quantitation Limit or BQL) in the composite 
dosed heart muscle samples. This is consistent with the idea that BDE-209 was mobilized 
from the yolk compartment through the vascular system of the developing embryo. The 
literature seems to suggest that BDE-209 is mobilized in the blood (Huwe et al. 2008) and is 
relatively high in avian muscle tissue. Liang et al. (2008) identified BDE-209 as the dominant 
PBDE congener in foraging chicken hens from an electronic waste recycling area in southern 
China. Liang et al. (2008) showed peak BDE-209 levels in muscle tissue of 17,977 ng/g lipid 
wt. The levels reported in the heart tissue were lower than skeletal muscle, with an average of 
1135 ng/g lw. Like the brain samples, very little sample was available for analysis, only 0.1 g 
per pool of four. Therefore, these samples were reduced in volume and pooled together to 
lower the detection limits. Again, there was a trade off here between statistical power and 
detection limit, the reason the samples were analyzed individually first. Since BDE-209 was 
not detected, the detection limit must be lowered to confirm this finding. However, when 
pooling tissues and concentrating extracts, one may also encounter additional matrix 
interference issues in the GC/MS.
The fact that BDE-209 was detected in all of the dosed carcass samples indicated that 
it spread from the yolk into the embryo during development. The most logical mechanism for 
this movement was through the blood. Van den Steen et al. (2007) monitored BDE-209 in the
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blood of adult starlings. The muscle tissue BDE-209 concentrations were two-fold the liver 
tissue BDE-209 concentrations in the Van den Steen study.
All of the liver samples from dosed eggs contained relatively high concentrations of 
BDE-209. The average concentration of 3600 ng/g lw represents about 7% of the total 20,000 
ng/egg dose. The presence of high levels of BDE-209 in the liver was anticipated. Many 
researchers have reported BDE-209 concentrations in liver tissue of wild or free-ranging 
birds. Jaspers et al. (2006) observed 68 ng/g lw of BDE-209 in the liver tissue of barn owls 
from Belguim. Luo et al. (2009) reported a mean BDE-209 concentration of 18 ng/g lw in 
liver tissue from chickens in South China. In a similar study, Liang et al. (2008) found 495 
ng/g lw in the liver of chickens at an electronics recycling site in South China. Chen et al. 
2007 detected the highest concentrations of BDE-209 in livers, of Chinese birds of prey, a 
mean value of 12,200 ng/g lw..
D.2.3: Other PBDEs detected
The three possible nona-BDEs (BDE-206, 207 and 208) were detected in all of the 
dosed yolk and liver samples. Nona-BDEs were not detected in any of the carcass, brain or 
heart muscle samples. The sum of the average concentrations for each of the individual nona- 
BDEs in the dosed liver samples was 741 ng/g lw. If this is added to the average liver BDE- 
209 concentration of 3600 ng/g lw the total would be 4340 ng/g lw. The average total lipid 
weight for the pooled liver samples was 0.40g. This amounts to 1736 ng BDE-209 in the liver 
compartment instead of 1440 ng. The change is relatively insignificant in calculating the 
percentage of the total dose, the new value is 8.7% versus the old value of 7.
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The sum of the average concentrations for each of the individual nona-BDEs in the 
dosed yolk samples was 1800 ng/g lw. If this is added to the average liver BDE-209 
concentration of 9000 ng/g lw the total would be 10,800 ng/g lw. The average total lipid 
weight for the pooled liver samples was 7g. This amounts to 75,000 ng BDE-209 in the yolk 
compartment.
In viewing the yolk samples individually, some interesting patterns emerge. As all of 
the samples represent a pool of four tissues, individual analysis can not be conducted. The 
pool becomes the experimental unit and may mask some of the variation that occurred within 
the individual embryos. Figure D.2 shows the BDE-209, -208, -207, and -206 trends in the 
yolk samples. Sample YD7 clearly exhibited the lowest levels of BDE-209 and the highest 
levels of all three nona-BDEs. This is the type of pattern one would expect to see if metabolic 
debromination was occurring in some embryos.
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Figure D.3: Mean Deca- and Nona-BDE concentrations in pooled liver, yolk, and 
carcass samples from BDE-209 dosed eggs
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In the yolk samples it is clear that BDE-206 is the dominant non-BDE congener. This 
is not the case in the liver samples. In the liver samples BDE-207 is the dominant nona-BDE 
congener. It is unclear if this is due to metabolic formation of BDE-207 in the liver. No octa- 
or hepta-BDEs or lower (other than BDE-166) were detected in any of the samples. A 
comparison of the congener profiles of the samples from this study and those of the available 
Deca-BDE commercial formulations is required. Figure D.4 shows the congener profiles of 
the two most common Deca-BDE products (LaGuardia et al., 2006).
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Figure D.4: Congener profiles of two commercial Deca-BDE formulations
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In both commercial Deca-BDE formulations presented in Figure D.4 BDE-206 is the 
dominant nona-BDE congener. The Bromkal 82-BDE product contains trace amounts of 
octa-BDEs (<0.5%). The Saytex 102E product does not contain octa-BDE impurities. No 
octa-BDEs were detected in any of the samples from this study. If the octa-BDEs were 
present then they were always BQL.
D.2.4: Other brominated compounds detected
The detection of an Octa-PBDF in three of the yolks samples raised some questions. 
There are several possibilities to explain the presence of this compound therein. One 
possibility is that an impurity existed within the BDE-209. Indeed, Hanari et al (2006) 
reported octabromodibenzofuran to be a substantial impurity of the commercial decaBDE 
product DE-83. It was the dominant brominated furan observed, present at up to 48 ng/g.
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Alternatively, the PBDF may have formed through photolytic breakdown of BDE-209 
during the analytical process. However, except for the lipid determination and final solvent 
volume reduction steps, the samples were always stored in amber glassware to prevent 
photolytic degradation of BDE-209. The literature indicates that PBDFs may be created by 
photolysis of BDE-209 (Hagberg et al. 2006; Kajiwara et al. 2008). Both of these studies 
identified numerous PBDFs in light-xposed BDE-209 samples. For example, Hagberg et al. 
(2006) identified 27 different PBDFs breakdown products. While they did not monitor the 
hepta- and octa- brominated PBDFs, Kajiwara et al. (2008) did in an experiment investigating 
the photolysis of BDE-209 in plastics. However, again multiple PBDF congeners were 
reported. The majority of these were the lesser brominated tri through hexa- PBDFs. This 
information leads this author to hypothesize that this single, fully-brominated PBDF was not 
formed through photolytic degradation as more samples would have likely been affected and 
additional PBDF congeners formed.
The third possibility for the occurrence of this furan was laboratory contamination. 
This can not be completely ruled out, but it also seems unlikely. Contamination of only five 
samples out of a total of 96 indicates that the contamination was not systematic in the 
analytical method. Furthermore, this compound is not kept in the laboratory inventory and is 
not used in commercial products. So, the contamination would have had to some from a light 
exposed solution of BDE-209 or other source. Quality control measures should have 
prevented this. Again, had the contamination come from a photolytically degraded BDE-209 
solution, it is likely that other furans would also be present.
A fourth possibility is that this furan was formed inside the embryo. Formation of this 
compound would require the loss of two bromines from the para- positions on each ring and
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the subsequent formation of the C-C bond between the two rings. The theorized mechanism 
for debromination in birds is the reductive debromination by 5’-MA (deiodinase), 
preferentially at the meta (5) position (Valverde et al. 1993). Therefore, the loss of two 
bromines from the para- positions can not be explained by this specific mechanism. The 
potential exists for an alternate mechanism within the embryo to explain this observation. 
However, the details of that mechanism are not understood.
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CONCLUSION:
The findings of these studies indicate that BDE-209 is toxic to chicken embryos when 
injected into the yolk, exhibiting an LD50 of 740 ng/g over a 20 day exposure via yolk 
injection. This is roughly 6000 times less toxic than TCDD to embryonic chickens. The 
distribution analysis of the five compartments (yolk, liver, brain, heart, and carcass) is 
consistent with published literature indicating that BDE-209 is transported by the blood 
throughout the embryo. No definitive evidence of metabolic debromination by chicken 
embryos was seen. Both tissue extracts and the dosing emulsion exhibited low levels of nona- 
BDE congeners. Highest BDE-209 concentrations were in the yolk at the conclusion of the 
study, day 20 (just prior to pipping). The yolk compartment acted as both a source (from the 
initial injection) and a likely sink (recipient of waste products) for BDE-209 and contributed 
to this result. A more complex distribution model (i.e. with more compartmentalization) is 
recommended for future similar work. In addition, I would recommend that the embryos be 
allowed to hatch, absorb all of their yolk and the BDE-209 in the yolk. Then sacrificed at 3-4 
days of age to determine how much of the administered dose actually ended up in tissues and 
how much was excreted and /or metabolized. This author believes a microsomal assay similar 
to that from Stapleton et al. (2006) could be used to address the question of metabolic 
debromination of BDE-209 by avian embryos.
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Appendix A: Moisture Weight Loss throughout Egg Incubations
Figure A.l: Moisture Weight Loss for Trial 1
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Error bars show standard deviation.
Figure A.3: Moisture Weight Loss in Trial 3 Non-Injected Eggs
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Figure A.4: Moisture Weight Loss in Trial 3 Vehicle Injected Eggs
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Figure A.5: Moisture Weight Loss in Trial 3 BDE-209 Injected Eggs
Moisture Weight Loss of Trial 3 Eggs Injected with BDE-209
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Appendix B: Conversion of Tissue Compartment Dry Weights to Wet Weights 
Figure B.l : Dry Weight Versus Wet Weights of Pooled Brain Samples
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Figure B.2: Dry Weight vs. Wet Weight for Pooled Carcass Samples
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Figure B.3 Comparison of sample dry weights to wet weights.
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Figure B.4: Heart Muscle Samples Wet Weight vs. Dry Weight
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Figure B.5: Yolk Samples Wet Weight vs. Dry Weight
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Appendix C: Mass Balance on an Individual Sample Basis
Sample Pool 1
Sample LD1 was lost during sample processing. Therefore, the mean liver 
concentration is used in these calculations. The data are presented in Table R.23. A total of 
48,800 ng of BDE-209 is accounted for in the form of BDE-209. A total of 8200 ng of BDE- 
209 can be accounted for in the form of the three Nona-BDEs. This leads to total detection of 
roughly 71% of the total administered dose to Sample Pool 1.
Table C.l: Sample Pool 1
BDE209
(ng/g
dw)
Total BDE-209(ng) in 
pooled Tissue Sample
Sum Nona-BDE; 
(ng/g dw)
Total Sum Nona-BDEs 
(ng) in pooled tissue  
sample
BD1 0 0 0 0
MD1 0 0 0 0
LD1 1800 1800 260 260
CD1 116 3000 0 0
YD1 220 44000 390 7900
SUM 48800 SUM 8160
Sample Pool 2
Table C.2: Sample Pool 2
BDE209
(ng/g
dw)
Total BDE- 
209(ng) in 
pooled Tissue 
Sample
Sum Nona- 
BDEs (ng/g 
dw)
Total Sum Nona- 
BDEs (ng) in 
pooled tissue  
sample
BD2 0 0 0 0
MD2 0 0 0 0
LD2 880 790 130 120
CD2 105 2900 0 0
YD2 3500 60000 470 8000
SUM 63690 SUM 8120
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Sample Pool 3
Table C.3: Sample Pool 3
BDE209
(ng/g
dw)
Total BDE-209(ng) 
in pooled Tissue 
Sample
Sum Nona- 
BDEs 
(ng/g dw)
Total Sum Nona- 
BDEs (ng) in 
pooled tissue  
sample
BD3 0 0 0 0
MD3 0 0 0 0
LD3 1000 110 230 250
CD3 110 2940 0 0
YD3 3100 68000 660 13600
SUM 71050 SUM 13850
Sample Pool 4
Table C.4: Sample Pool 4
BDE209
(ng/g
dw)
Total BDE- 
209(ng) in 
pooled Tissue 
Sample
Sum Nona- 
BDEs (ng/g 
dw)
Total Sum Nona- 
BDEs (ng) in 
pooled tissue  
sample
BD4 0 0 0 0
MD4 0 0 0 0
LD4 1850 1850 370 370
CD4 80 2200 0 0
YD4 3900 74880 410 7900
SUM 78930 SUM 8270
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Sample Pool 5
Table A.5: Sample Pool 5
BDE209
(ng/g
dw)
Total BDE- 
209(ng) in 
pooled Tissue 
Sample
Sum Nona- 
BDEs (ng/g 
dw)
Total Sum Nona- 
BDEs (ng) in pooled 
tissue sample
BD5 0 0 0 0
MD5 0 0 0 0
LD5 1170 1170 220 220
CD5 70 1780 0 0
YD5 3700 74400 370 7400
SUM 77350 SUM 7620
Sample Pool 6
Table C.6: Sample Pool 6
BDE209
(ng/g
dw)
Total BDE- 
209(ng) in 
pooled Tissue  
Sample
Sum
Nona-
BDEs
(ng/g
dw)
Total Sum Nona- 
BDEs (ng) in 
pooled tissue  
sample
BD6 0 0 0 0
MD6 0 0 0 0
LD6 2600 2340 39 0 351
CD6 140 3800 0 0
YD6 4100 70500 370 6400
SUM 76640 SUM 6751
Sample Pool 7
Table C.7: Sample Pool 7
BDE209
(ng/g
dw)
Total BDE-209(ng) 
in pooled Tissue  
Sample
Sum Nona- 
BDEs (ng/g 
dw)
Total Sum Nona- 
BDEs (ng) in 
pooled tissue  
sample
BD7 0 0 0 0
MD7 0 0 0 0
LD7 1840 1660 430 390
CD7 97 2400 0 0
YD7 4200 80600 1400 26880
SUM 84660 SUM 27270
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Sample Pool 8
Table C.8: Sample Pool 8
BDE209
(ng/g
dw)
Total BDE- 
209(ng) in 
pooled Tissue 
Sample
Sum 
Nona- 
BDEs 
(ng/g dw)
Total Sum Nona- 
BDEs (ng) in 
pooled tissue  
sample
BD8 0 0 0 0
MD8 0 0 0 0
LD8 1900 1710 210 190
CD8 320 8400 0 0
YD8 3860 63700 380 6270
SUM 73810 SUM 6460
115
VITA
Samantha D. Sifleet
Bom in Concord Massachusetts on May 22, 1980. Earned her B.S. from the 
University of Massachusetts in Ecology, Sustainability and Pre-Law in May 2003. Entered 
into a concurrent M.S and M.P.P program at the College of William and Mary School of 
Marine Science and the Thomas Jefferson Program in Public Policy in 2005.
116
